Anti PD-1 antibody to be used in treatment method of recurrent small cell lung cancer

Combining anti-PD-1 and anti-CTLA-4 antibodies effectively treats SCLC by inhibiting immune checkpoints, enhancing survival outcomes and addressing the limitations of current therapies.

JP2024167282AInactive Publication Date: 2024-12-03BRISTOL MYERS SQUIBB CO
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
JP2024141986
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2016-06-03
Filing Date
2024-08-23
Publication Date
2024-12-03
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Small cell lung cancer (SCLC) is characterized by extensive metastases and poor survival outcomes, with limited effectiveness of current second-line treatments, necessitating the development of more effective therapeutic strategies.

Method used

Administering a combination of anti-PD-1 and anti-CTLA-4 antibodies to inhibit immune checkpoint pathways, specifically using nivolumab and ipilimumab or their antigen-binding portions, to treat SCLC, with dosing regimens tailored for optimal clinical benefit.

Benefits of technology

The combination therapy prolongs progression-free survival and overall survival in SCLC patients, demonstrating significant improvement over standard treatments, particularly in tumors with high PD-L1 expression.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024167282000015
    Figure 2024167282000015
  • Figure 2024167282000016
    Figure 2024167282000016
  • Figure 2024167282000017
    Figure 2024167282000017
Patent Text Reader

Abstract

To provide a method for treating a subject having a tumor derived from a small cell lung cancer.SOLUTION: A method includes administering to a subject an antibody or an antigen-binding portion thereof that specifically binds to a Programmed Death-1 (PD-1) receptor, and inhibits PD-1 activity or a combination of (a) an antibody or an antigen-binding portion thereof that specifically binds to the PD-1 receptor, and inhibits PD-1 activity; and (b) an antibody or an antigen-binding portion thereof that specifically binds to a Cytotoxic T-lymphocyte Antigen-4 (CTLA-4), and inhibits CTLA-4 activity.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] FIELD OF THEINVENTION The present invention relates to a method of treating a tumor resulting from small cell lung cancer in a subject, comprising administering to the subject an anti-Programmed Death-1 (PD-1) antibody or a combination of an anti-PD-1 antibody and an anti-Cytotoxic T-Lymphocyte Antigen-4 (CTLA-4) antibody. [Background technology]

[0002] 2. Background of the Invention Human cancers harbor numerous genetic and epigenetic alterations, generating potential neo-antigens that can be recognized by the immune system (Sjoblom et al., (2006) Science 314:268-74). The adaptive immune system, consisting of T and B lymphocytes, has a broad capacity and exquisite specificity to respond to diverse tumor antigens and has potent anti-cancer potential. Furthermore, the immune system exhibits considerable plasticity and memory components. The successful exploitation of all these attributes of the adaptive immune system makes immunotherapy unique among all cancer treatment modalities.

[0003] PD-1 is an important immune checkpoint receptor expressed by activated T and B cells and mediates immune suppression. PD-1 is a member of the CD28 family of receptors that includes CD28, CTLA-4, ICOS, PD-1, and BTLA. Two cell surface glycoprotein ligands for PD-1, programmed death ligand-1 (PD-L1) and programmed death ligand-2 (PD-L2), have been identified and are expressed on antigen-presenting cells as well as many human cancers, and have been shown to downregulate T cell activation and cytokine secretion upon binding to PD-1.

[0004] Nivolumab (previously named 5C4, BMS-936558, MDX-1106 or ONO-4538) is a fully human IgG4(S228P)PD-1 immune checkpoint inhibitor antibody that selectively inhibits the interaction with PD-1 ligands (PD-L1 and PD-L2), thereby blocking the downregulation of antitumor T cell function (U.S. Patent 8,008,449; Wang et al., 2014 Cancer Immunol Res. 2(9):846-56).

[0005] Ipilimumab (Yervoy (登録商標) ) is a fully human, IgG1 monoclonal antibody that blocks the binding of CTLA-4 to its B7 ligand, thereby stimulating T cell activation and improving overall survival (OS) in patients with advanced melanoma (Hodi et al. (2010) N Engl J Med 363:711-23). ​​Cotreatment of nivolumab and ipilimumab in a phase 1 trial produced rapid and profound tumor regression in a substantial proportion of patients with advanced melanoma and was significantly more effective than either antibody alone (Wolchok et al. (2013) N Engl J Med 369(2):122-33; WO2013 / 173223). However, to date, it has not been known whether this combination of immune-regulatory reversal would be similarly effective in the treatment of small cell lung cancer (SCLC). Summary of the Invention [Problem to be solved by the invention]

[0006] SCLC accounts for approximately 14% of all lung cancers (Byers and Rudin, Cancer 121:664-72 (2015)). Most patients present with extensive disease, characterized by widespread metastases and limited survival. Although 35%-86% of patients respond to first-line chemotherapy, the disease progresses rapidly and outcomes with second-line treatment are poor (Hanna et al., J. Clin. Oncol. 24:2038-43 (2006); Puglisi et al., Br. J. Cancer 102:629-38 (2010); Zatloukal et al., Ann. Oncol. 21:1810-16 (2010)). Thus, there is a need for effective therapies for the treatment of SCLC, especially second-line therapies for patients who relapse after initial treatment. [Means for solving the problem]

[0007] Summary of the Invention The present invention relates to methods of treating a subject having a tumor resulting from small cell lung cancer (SCLC), comprising administering to the subject (a) a combination of antibodies or antigen-binding portions thereof that specifically bind to the Programmed Death-1 (PD-1) receptor and inhibit PD-1 activity ("anti-PD-1 antibodies").

[0008] Another aspect of the invention relates to a method of treating a subject having a tumor derived from SCLC, comprising administering to the subject a combination of (a) an anti-PD-1 antibody and (b) an antibody or antigen-binding portion thereof that specifically binds to cytotoxic T-lymphocyte antigen-4 (CTLA-4) and inhibits CTLA-4 activity (an "anti-CTLA-4 antibody").

[0009] In some embodiments, the anti-PD-1 antibody cross-competes with nivolumab for binding to human PD-1. In some embodiments, the anti-PD-1 antibody is a chimeric, humanized or human monoclonal antibody or a portion thereof. In other embodiments, the anti-PD-1 antibody comprises a heavy chain constant region of human IgG1 or IgG4 isotype. In some embodiments, the anti-PD-1 antibody is nivolumab. In some embodiments, the anti-PD-1 antibody is pembrolizumab.

[0010] In some embodiments, the anti-CTLA-4 antibody is a chimeric, humanized or human monoclonal antibody or a part thereof.In some embodiments, the anti-CTLA-4 antibody comprises a heavy chain constant region that is human IgG1 isotype.In some embodiments, the anti-CTLA-4 antibody is ipilimumab.In other embodiments, the anti-CTLA-4 antibody is tremelimumab.In some embodiments, the anti-CTLA-4 antibody cross-competes with ipilimumab for binding to human CTLA-4.

[0011] In certain embodiments, the anti-PD-1 antibody or antigen-binding portion thereof is administered at a dose of about 1 mg / kg or about 3 mg / kg body weight about once every two weeks. In other embodiments, the anti-PD-1 antibody or antigen-binding portion thereof is administered at a dose of about 1 mg / kg or about 3 mg / kg body weight about once every three weeks. In certain embodiments, the anti-CTLA-4 antibody or antigen-binding portion thereof is administered at a dose of about 1 mg / kg or about 3 mg / kg body weight. In other embodiments, the anti-PD-1 antibody or antigen-binding portion thereof is administered at a dose of about 3 mg / kg body weight about once every three weeks, and the anti-CTLA-4 antibody or antigen-binding portion thereof is administered at a dose of about 1 mg / kg body weight about once every three weeks. In certain embodiments, the anti-PD-1 antibody or antigen-binding portion thereof is administered at a dose of about 1 mg / kg body weight about once every three weeks, and the anti-CTLA-4 antibody or antigen-binding portion thereof is administered at a dose of about 3 mg / kg body weight about once every three weeks.

[0012] In certain embodiments, the subject treated by the methods of the present invention exhibits progression-free survival of at least about 1 month, at least about 2 months, at least about 3 months, at least about 4 months, at least about 5 months, at least about 6 months, at least about 7 months, at least about 8 months, at least about 9 months, at least about 10 months, at least about 11 months, at least about 1 year, at least about 18 months, at least about 2 years, at least about 3 years, at least about 4 years, or at least about 5 years. In certain embodiments, the subject exhibits progression-free survival of at least about 8 months after the first administration.

[0013] In some embodiments, the subject has a lung tumor with ≥ 1% PD-L1 expression. In some embodiments, the anti-PD-1 antibody or anti-PD-1 antibody and anti-CTLA-4 combination is administered as long as clinical benefit is observed or until disease progression or unmanageable toxicity occurs. In some embodiments, the anti-PD-1 and / or anti-CTLA-4 antibody is formulated for intravenous administration. In some embodiments, the anti-PD-1 antibody and anti-CTLA-4 antibody are administered sequentially to the subject. In some embodiments, the anti-PD-1 and anti-CTLA-4 antibodies are administered within 30 minutes of each other. In some embodiments, the anti-PD-1 antibody is administered before the anti-CTLA-4 antibody. In other embodiments, the anti-CTLA-4 antibody is administered before the anti-PD-1 antibody. In some embodiments, the anti-PD-1 antibody and anti-CTLA-4 antibody are administered simultaneously in separate compositions. In some embodiments, the anti-PD-1 antibody and anti-CTLA-4 antibody are administered simultaneously as a single composition.

[0014] In certain embodiments, the anti-PD-1 antibody is administered at a sub-therapeutic dose. In certain embodiments, the anti-CTLA-4 antibody is administered at a sub-therapeutic dose. In certain embodiments, the anti-PD-1 antibody and the anti-CTLA-4 antibody are each administered at a sub-therapeutic dose.

[0015] The invention further relates to a kit for treating a subject having a tumor derived from SCLC, the kit comprising: (a) an anti-PD-1 antibody in an amount ranging from about 4 mg to about 500 mg; and (b) instructions for using the PD-1 antibody in a method of the invention.

[0016] The present invention further relates to a kit for treating a subject having a tumor derived from SCLC, the kit comprising: (a) an anti-PD-1 antibody in an amount ranging from about 4 mg to about 500 mg; (b) a CTLA-4 antibody in an amount ranging from about 4 mg to about 500 mg; and (c) instructions for using the PD-1 antibody and the CTLA-4 antibody in a method of the invention.

[0017] Other features and advantages of the present invention will be apparent from the following detailed description and examples, which should not be construed as limiting. The entire contents of all cited references, including scientific articles, journal articles, GenBank entries, patents, and patent applications cited throughout this specification are expressly incorporated herein by reference.

[0018] Implementation E1. A method of treating a subject having a tumor derived from small cell lung cancer (SCLC), comprising administering to the subject an antibody or antigen-binding portion thereof that specifically binds to the Programmed Death-1 (PD-1) receptor and inhibits PD-1 activity (an "anti-PD-1 antibody").

[0019] E2. The method of embodiment E1, further comprising administering to the subject an antibody or antigen-binding portion thereof that specifically binds to cytotoxic T-lymphocyte antigen-4 (CTLA-4) and inhibits CTLA-4 activity (an "anti-CTLA-4 antibody").

[0020] E3. The method of embodiment E1 or E2, wherein the SCLC comprises small cell carcinoma.

[0021] E4. The method of embodiment E1 or E2, wherein the SCLC comprises mixed small cell carcinoma.

[0022] E5. The method of any of embodiments E1-E4, wherein the SCLC is recurrent SCLC.

[0023] E6. The method of any of embodiments E1-E5, wherein the subject has undergone at least one, at least two, at least three, at least four, or at least five lines of prior therapy to treat the tumor.

[0024] E7. The method of embodiment E6, wherein the prior line of treatment comprises a chemotherapeutic agent.

[0025] E8. The method of embodiment E7, wherein the chemotherapeutic agent comprises a platinum-based therapy.

[0026] E9. The method of embodiment E8, wherein the platinum-based therapy comprises a platinum-based anti-neoplastic selected from the group consisting of cisplatin, carboplatin, oxaliplatin, nedaplatin, triplatin tetranitrate, phenanthriplatin, picoplatin, satraplatin, and any combination thereof.

[0027] E10. The method of embodiment E7 or E8, wherein the platinum-based therapy comprises cisplatin.

[0028] E11. The method of any of embodiments E1-E10, wherein the anti-PD-1 antibody cross-competes with nivolumab for binding to human PD-1.

[0029] E12. The method of any of embodiments E1-E11, wherein the anti-PD-1 antibody binds to the same epitope as nivolumab.

[0030] E13. The method of any of embodiments E1-E12, wherein the anti-PD-1 antibody is a chimeric, humanized or human monoclonal antibody or portion thereof.

[0031] E14. The method of any of embodiments E1-E13, wherein the anti-PD-1 antibody comprises a heavy chain constant region that is of the human IgG1 or IgG4 isotype.

[0032] E15. The method of any of embodiments E1-E14, wherein the anti-PD-1 antibody is nivolumab.

[0033] E16. The method of any of embodiments E1-E14, wherein the anti-PD-1 antibody is pembrolizumab.

[0034] E17. The method of any of embodiments E2-E16, wherein the anti-CTLA-4 antibody is a chimeric, humanized or human monoclonal antibody or portion thereof.

[0035] E18. The method of any of embodiments E2-E17, wherein the anti-CTLA-4 antibody comprises a heavy chain constant region that is a human IgG1 isotype.

[0036] E19. The method of any of embodiments E2-E18, wherein the anti-CTLA-4 antibody is ipilimumab.

[0037] E20. The method of any of embodiments E2-E18, wherein the anti-CTLA-4 antibody is tremelimumab.

[0038] E21. The method of any of embodiments E2-E20, wherein the anti-CTLA-4 antibody cross-competes with ipilimumab for binding to human CTLA-4.

[0039] E22. The method of any of embodiments E1-E21, wherein the anti-PD-1 antibody is administered at a dose ranging from at least about 0.1 mg / kg to at least about 10.0 mg / kg body weight about once every 1, 2, 3, or 4 weeks.

[0040] E23. The method of any of embodiments E1-E22, wherein the anti-PD-1 antibody is administered at a dose of about 1 mg / kg or about 3 mg / kg body weight.

[0041] E24. The method of any of embodiments E1-E21, wherein the anti-PD-1 antibody, or antigen-binding portion thereof, is administered in a flat dose.

[0042] E25. The method of any of embodiments E1-E21, and E24, wherein the anti-PD-1 antibody, or antigen-binding portion thereof, is administered in a uniform dose of at least about 200 mg, at least about 220 mg, at least about 240 mg, at least about 260 mg, at least about 280 mg, at least about 300 mg, at least about 320 mg, at least about 340 mg, at least about 360 mg, at least about 380 mg, at least about 400 mg, at least about 420 mg, at least about 440 mg, at least about 460 mg, at least about 480 mg, at least about 500 mg, or at least about 550 mg.

[0043] E26. The method of any of embodiments E1-E21, E24, and E25, wherein the anti-PD-1 antibody, or antigen-binding portion thereof, is administered in a flat dose about once every 1 week, 2 weeks, 3 weeks, or 4 weeks.

[0044] E27. The method of any of embodiments E1-E26, wherein the anti-PD-1 antibody is administered about once every two weeks.

[0045] E28. The method of any of embodiments E1-E26, wherein the anti-PD-1 antibody is administered about once every three weeks.

[0046] E29. The method of any of embodiments E1-E28, wherein the anti-PD-1 antibody is administered for as long as clinical benefit is observed or until unmanageable toxicity or disease progression occurs.

[0047] E30. The method of any of embodiments E2-E29, wherein the anti-CTLA-4 antibody is administered at a dose ranging from at least about 0.1 mg / kg to at least about 10.0 mg / kg body weight about once every 1, 2, 3, or 4 weeks.

[0048] E31. The method of any of embodiments E2-E30, wherein anti-CTLA-4 is administered at a dose of about 1 mg / kg or about 3 mg / kg body weight.

[0049] E32. The method of any of embodiments E2-E31, wherein the anti-PD-1 antibody, or antigen-binding portion thereof, is administered in a flat dose.

[0050] E33. The method of any of embodiments E2-E32, wherein the anti-CTLA-4 antibody is administered about once every two weeks.

[0051] E34. The method of any of embodiments E2-E32, wherein the anti-CTLA-4 antibody is administered about once every three weeks.

[0052] E35. The method of any of embodiments E2-E34, wherein the anti-PD-1 antibody is administered at a dose of about 3 mg / kg body weight about once every three weeks, and the anti-CTLA-4 antibody, or antigen-binding portion thereof, is administered at a dose of about 1 mg / kg body weight about once every three weeks.

[0053] E36. The method of any of embodiments E2-E34, wherein the anti-PD-1 antibody is administered at a dose of about 1 mg / kg body weight about once every three weeks, and the anti-CTLA-4 antibody, or antigen-binding portion thereof, is administered at a dose of about 3 mg / kg body weight about once every three weeks.

[0054] E37. The method of any of embodiments E1-E36, wherein the subject exhibits progression free survival for at least about 1 month, at least about 2 months, at least about 3 months, at least about 4 months, at least about 5 months, at least about 6 months, at least about 7 months, at least about 8 months, at least about 9 months, at least about 10 months, at least about 11 months, at least about 1 year, at least about 18 months, at least about 2 years, at least about 3 years, at least about 4 years, or at least about 5 years after initiation of administration.

[0055] E38. The method of any of embodiments E1-E37, wherein the subject has a tumor with ≧1% PD-L1 expression.

[0056] E39. The method of any of embodiments E1-E38, wherein the subject has a tumor with ≧5% PD-L1 expression.

[0057] E40. The method of any of embodiments E2-E39, wherein the combination is administered for as long as clinical benefit is observed or until disease progression or unmanageable toxicity occurs.

[0058] E41. The method of any of embodiments E1-E40, wherein the anti-PD-1 antibody is formulated for intravenous administration.

[0059] E42. The method of any of embodiments E2-E41, wherein the anti-CTLA-4 antibody is formulated for intravenous administration.

[0060] E43. The method of any of embodiments E2-E42, wherein the anti-PD-1 antibody and the anti-CTLA-4 antibody are administered to the subject sequentially.

[0061] E44. The method of any of embodiments E2-43, wherein the anti-PD-1 and anti-CTLA-4 antibodies are administered within 30 minutes of each other.

[0062] E45. The method of any of embodiments E2-E44, wherein the anti-PD-1 antibody, or antigen-binding portion thereof, is administered prior to the anti-CTLA-4 antibody, or antigen-binding portion thereof.

[0063] E46. The method of any of embodiments E2-E44, wherein the anti-CTLA-4 antibody, or antigen-binding portion thereof, is administered prior to the anti-PD-1 antibody, or antigen-binding portion thereof.

[0064] E47. The method of any of embodiments E2-E42, wherein the anti-PD-1 antibody, or antigen-binding portion thereof, and the anti-CTLA-4 antibody, or antigen-binding portion thereof, are administered simultaneously in separate compositions.

[0065] E48. The method of any of embodiments E2-E42, wherein the anti-PD-1 antibody, or antigen-binding portion thereof, and the anti-CTLA-4 antibody, or antigen-binding portion thereof, are administered simultaneously as a single composition.

[0066] E49. The method of any of embodiments E1-E48, wherein the anti-PD-1 antibody, or antigen-binding portion thereof, is administered in a subtherapeutic dose.

[0067] E50. The method of any of embodiments E2-E49, wherein the anti-CTLA-4 antibody, or antigen-binding portion thereof, is administered in a subtherapeutic dose.

[0068] E51. The method of any of embodiments E2-E50, wherein the anti-PD-1 antibody, or antigen-binding portion thereof, and the anti-CTLA-4 antibody, or antigen-binding portion thereof, are each administered in a subtherapeutic dose.

[0069] E52. A kit for treating a subject having a tumor derived from SCLC, comprising: (a) an anti-PD-1 antibody, or antigen-binding portion thereof, in an amount ranging from about 4 mg to about 500 mg; and (b) Instructions for using a PD-1 antibody in the method of any of embodiments E1 to E51. Includes.

[0070] E53. A kit for treating a subject having a tumor derived from SCLC, comprising: (a) an anti-PD-1 antibody, or antigen-binding portion thereof, in an amount ranging from about 4 mg to about 500 mg; (b) a CTLA-4 antibody or antigen-binding portion thereof in an amount of about 4 mg to about 500 mg; and (c) Instructions for using a PD-1 antibody and a CTLA-4 antibody according to the method of any of embodiments E2 to E51. Including the kit. [Brief description of the drawings]

[0071] [Figure 1] FIG. 1 outlines the clinical trial design for the treatment of tumors derived from SCLC using anti-PD-1 antibodies or a combination of anti-PD-1 and anti-CTLA-4 antibodies.

[0072] [Diagram 2] Figures 2A and 2B show images of tumors derived from SCLC found in the lungs of a subject before (Figure 2A) and after (Figure 2B) treatment with a combination of nivolumab 1 mg / kg body weight and ipilimumab 3 mg / kg body weight. The tumor tissue is circled in both Figures 2A and 2B.

[0073] [Figure 3-1]Figures 3A-3C provide graphical representations of the change in tumor burden in individual patients receiving nivolumab 3 mg / kg (Figure 3A), nivolumab 1 mg / kg + ipilimumab 3 mg / kg (Figure 3B), and nivolumab 3 mg / kg + ipilimumab 1 mg / kg (Figure 3C). Only patients with target lesions at baseline and at least one on-treatment tumor assessment were included (nivolumab 3 mg / kg, n=80; nivolumab 1 mg / kg + ipilimumab 3 mg / kg, n=46; nivolumab 3 mg / kg + ipilimumab 1 mg / kg, n=47). The horizontal grey line indicates a 30% reduction consistent with Response Evaluation Criteria in Solid Tumors (RECIST; version 1.1) objective response. Subjects who demonstrated a complete response (CR) or partial response (PR) are marked with an inverted triangle at the time of PR or CR. The + marks the first appearance of new lesions and the open circles indicate the time points when subjects stopped treatment. Measurements greater than 100% are truncated to 100% and data points are represented by open squares. [Figure 3-2] Same as above.

[0074] [Figure 4A] Figures 4A and 4B provide Kaplan-Meier curves for overall survival (Figure 4A) and progression-free survival (Figure 4B) for subjects treated with nivolumab 3 mg / kg (circles), nivolumab 1 mg / kg + ipilimumab 3 mg / kg (diamonds), and nivolumab 3 mg / kg + ipilimumab 1 mg / kg (triangles). The number of subjects at risk and the number of censored patients are shown below the y-axis for each treatment (Figures 4A and 4B). [Figure 4B] Same as above.

[0075] [Figure 5-1]Figures 5A-5C provide a graphical representation of the change in tumor burden by tumor PD-L1 expression status. Percent change from baseline for tumors with <1% PD-L1 expression is shown in grey and for tumors with >= 1% PD-L1 expression is shown in black. Changes in baseline for tumors where PD-L1 expression was not assessed or missing are shown in light grey. Black circles above bars indicate confirmed responders. Open boxes indicate % change truncated to 100%. [Figure 5-2] Same as above.

[0076] [Figure 6A] Figures 6A-6D show Kaplan-Meier curves of overall survival (Figures 6A and 6B) and progression-free survival (Figures 6C and 6D) for subjects with one prior treatment (Figures 6A and 6C) and two or more prior treatments (Figures 6B and 6D). Subjects were treated with nivolumab 3 mg / kg (circles), nivolumab 1 mg / kg + ipilimumab 3 mg / kg (diamonds) or nivolumab 3 mg / kg + ipilimumab 1 mg / kg (triangles). The number of subjects at risk and the number of censored patients are shown below the y-axis for each treatment (Figures 6A-6D). [Figure 6B] Same as above. [Figure 6C] Same as above. [Figure 6D] Same as above.

[0077] [Figure 7A]Figures 7A-7C provide graphical representations of tumor burden change by platinum sensitivity in individual patients receiving nivolumab 3 mg / kg (Figure 7A), nivolumab 1 mg / kg + ipilimumab 3 mg / kg (Figure 7B), and nivolumab 3 mg / kg + ipilimumab 1 mg / kg (Figure 7C) (platinum-sensitive tumors are shown as grey lines, platinum-resistant tumors are shown as black lines). Only patients with target lesions at baseline and ≥ 1 on-treatment tumor assessment were included (nivolumab-3, n = 31; nivolumab-1 / ipilimumab-3, n = 21; nivolumab-3 / ipilimumab-1, n = 17). Panels show tumor burden (assessed as the longest linear dimension) over time in patients receiving second-line nivolumab-3 (Figure 7A), nivolumab-1 / ipilimumab-3 (Figure 7B) and nivolumab-3 / ipilimumab-1 (Figure 7C). Horizontal reference lines indicate a 30% reduction consistent with RECIST (version 1.1) objective response. Subjects who achieved a complete response (CR) or partial response (PR) are marked with an inverted triangle at the time of PR or CR. A + sign indicates the first appearance of new lesions and an open circle indicates the time at which the subject discontinued treatment. Measurements greater than 100% are truncated to 100% and data points are represented by open squares. [Figure 7B] Same as above. [Figure 7C] Same as above.

[0078] [Figure 8] FIG. 8 outlines the clinical trial design for the treatment of tumors derived from SCLC using anti-PD-1 antibodies or a combination of anti-PD-1 and anti-CTLA-4 antibodies, including randomized and non-randomized cohorts.

[0079] [Figure 9] Figure 9 shows Kaplan-Meier curves for overall survival of subjects treated with nivolumab 3 mg / kg (circles) or nivolumab 1 mg / kg + ipilimumab 3 mg / kg (diamonds). The number of subjects at risk is shown below the y-axis for each treatment.

[0080] [Figure 10]Figure 10 provides a graphical representation of the overall response rate (ORR) observed in patients treated with nivolumab 1 mg / kg or nivolumab 1 mg / kg + ipilimumab 3 mg / kg in the randomized and non-randomized cohorts. Nivo = nivolumab; ipi = ipilimumab.

[0081] [Figure 11] Figure 11 provides a graphical representation of the progression-free survival (PFS) rates observed in patients treated with nivolumab 3 mg / kg or nivolumab 1 mg / kg + ipilimumab 3 mg / kg in the randomized and non-randomized cohorts. Nivo = nivolumab; ipi = ipilimumab.

[0082] [Figure 12] Figure 12 shows a graphical representation of the overall survival (OS) rates observed in patients treated with nivolumab 3 mg / kg or nivolumab 1 mg / kg + ipilimumab 3 mg / kg in randomized and non-randomized cohorts. Nivo = nivolumab; ipi = ipilimumab. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0083] Detailed Description of the Invention The present invention relates to a method of treating a tumor derived from SCLC in a patient comprising administering to the patient an anti-PD-1 antibody or a combination of an anti-PD-1 antibody and an anti-CTLA-4 antibody.

[0084] term In order that the present invention may be more readily understood, certain terms are first defined. As used herein, unless expressly indicated otherwise herein, each of the following terms has the meaning set forth below. Additional definitions are set forth throughout the specification.

[0085] "Administering" refers to physically introducing a composition comprising a therapeutic agent into a subject using any of a variety of methods and delivery systems known to those skilled in the art. Routes of administration of anti-PD-1 antibodies include intravenous, intramuscular, subcutaneous, intraperitoneal, spinal or other parenteral routes of administration, for example, by injection or infusion. As used herein, the term "parenteral administration" refers to modes of administration other than enteral and topical administration, typically by injection, including, but not limited to, intravenous, intramuscular, intraarterial, intrathecal, intralymphatic, intralesional, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal, epidural and intrasternal injection and infusion, and in vivo electroporation. In certain embodiments, the combination is administered by a non-parenteral route, in certain embodiments, orally. Other non-parenteral routes include topical, epithelial or mucosal routes of administration, for example, intranasal, vaginal, rectal, sublingual or topical. Administration can also be, for example, once, multiple times and / or one or more times over an extended period of time.

[0086] As used herein, an "adverse event" (AE) is any unfavourable, generally unintended or undesirable sign (including any laboratory finding), symptom or disease associated with the use of a medical treatment. For example, an adverse event may be related to immune system activation or immune system cell (e.g., T cell) expansion in response to the treatment. A medical treatment may have one or more associated AEs, and the severity level of each AE may be the same or different. Description of a method that can "modify an adverse event" refers to a treatment regimen that reduces the incidence and / or severity of one or more AEs associated with the use of a different treatment regimen.

[0087] An "antibody" (Ab) shall include, but is not limited to, a glycoprotein immunoglobulin or antigen-binding portion thereof that specifically binds an antigen and comprises at least two heavy (H) chains and two light (L) chains interconnected by disulfide bonds. Each H chain comprises a heavy chain variable region (herein referred to as V H The heavy chain constant region comprises at least three constant domains, C H1 , C H2 and C H3Each light chain comprises a light chain variable region (herein V L The light chain constant region comprises one constant domain, C L Includes: V H and V L The regions can be further subdivided into regions of hypervariability interspersed with more conserved regions called framework regions (FR). H and V L contains 3 CDRs and 4 FRs, arranged from amino terminus to carboxy terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3 and FR4. The variable regions of the heavy and light chains contain a binding domain that interacts with an antigen. The constant region of the antibody may mediate the binding of the immunoglobulin to host tissues or factors, including various cells of the immune system (e.g., effector cells) and the first component (C1q) of the classical complement pathway.

[0088] Immunoglobulins may be derived from any of the commonly known isotypes, including, but not limited to, IgA, secretory IgA, IgG, and IgM. IgG subclasses are well known to those skilled in the art and include, but are not limited to, human IgG1, IgG2, IgG3, and IgG4. "Isotype" refers to the antibody class or subclass (e.g., IgM or IgG1) that is encoded by the heavy chain constant region genes. The term "antibody" includes, by way of example, both naturally occurring and non-naturally occurring antibodies; monoclonal and polyclonal antibodies; chimeric and humanized antibodies; human or non-human antibodies; fully synthetic antibodies; and single chain antibodies. Non-human antibodies may be humanized by recombinant methods to reduce immunogenicity in humans. Unless expressly stated and unless otherwise indicated by context, the term "antibody" also includes antigen-binding fragments or portions of any of the above immunoglobulins, including monovalent and bivalent fragments or portions and single chain antibodies.

[0089] An "isolated antibody" refers to an antibody that is substantially free of other antibodies having different antigenic specificities (e.g., an isolated antibody that specifically binds PD-1 is substantially free of antibodies that specifically bind to antigens other than PD-1). An isolated antibody that specifically binds PD-1 may, however, have cross-reactivity with other antigens, such as PD-1 molecules from different species. Moreover, an isolated antibody may be substantially free of other cellular material and / or chemicals.

[0090] The term "monoclonal antibody" (mAb) refers to a preparation of non-naturally occurring antibody molecules of single molecular composition, i.e., antibody molecules which are essentially identical in primary sequence and which display a single binding specificity and affinity for a particular epitope. A monoclonal antibody is an example of an isolated antibody. MAbs may be produced by hybridoma, recombinant, transgenic, or other techniques known to those skilled in the art.

[0091] A "human antibody" (HuMAb) refers to an antibody having a variable region in which both the FRs and CDRs are derived from human germline immunoglobulin sequences. Furthermore, if the antibody contains a constant region, the constant region also is derived from human germline immunoglobulin sequences. The human antibodies of the invention may include amino acid residues not encoded by human germline immunoglobulin sequences (e.g., mutations introduced by random or site-specific mutagenesis in vitro or by somatic mutation in vivo). However, as used herein, the term "human antibody" is not intended to include antibodies in which CDR sequences from other mammalian species, such as mouse, have been grafted onto human framework sequences. The terms "human antibody" and "fully human antibody" are used interchangeably.

[0092] "Humanized antibody" refers to an antibody in which some, most or all of the amino acids outside the CDRs of a non-human antibody are replaced with the corresponding amino acids from a human immunoglobulin. In some embodiments of humanized forms of antibodies, some, most or all of the amino acids outside the CDRs are replaced with human immunoglobulin, while some, most or all of the amino acids within one or more CDRs remain unchanged. Small additions, deletions, insertions, substitutions or modifications of amino acids are permitted as long as they do not abolish the ability of the antibody to bind to a particular antigen. A "humanized antibody" maintains antigen specificity similar to that of the original antibody. In some embodiments, the CDRs of a humanized antibody comprise the CDRs of a non-human mammalian antibody. In other embodiments, the CDRs of a humanized antibody comprise the CDRs from an engineered synthetic antibody.

[0093] A "chimeric antibody" refers to an antibody in which the variable region is derived from one species and the constant region is derived from another species, such as the variable region being derived from a mouse antibody and the constant region being derived from a human antibody.

[0094] An "anti-antibody" refers to an antibody that specifically binds to an antigen. For example, an anti-PD-1 antibody specifically binds to PD-1, and an anti-CTLA-4 antibody specifically binds to CTLA-4.

[0095] An "antigen-binding portion" of an antibody (also called an "antigen-binding fragment") refers to one or more fragments of an antibody that retain the ability to specifically bind to the antigen bound by the whole antibody.

[0096] "Cancer" refers to a broad group of different diseases characterized by the uncontrolled growth of abnormal cells in the body. "Cancer" or "cancerous tissue" can include tumors. Uncontrolled cell division and growth leads to the formation of malignant tumors that can invade nearby tissues and also metastasize to distant sites via the lymphatic system or bloodstream. After metastasis, the distant tumor can be said to "originate" from the original pre-metastatic tumor. For example, a tumor "originating" from an SCLC refers to a tumor that is the result of a metastatic SCLC. Because a distant tumor originates from a metastatic tumor, "originating" from a tumor can also include a pre-metastatic tumor, for example, a tumor originating from an SCLC can include an SCLC.

[0097] "Cytotoxic T-lymphocyte antigen-4" (CTLA-4) refers to an immunoinhibitory receptor belonging to the CD28 family. CTLA-4 is expressed exclusively on T cells in vivo and binds to two ligands, CD80 and CD86 (also known as B7-1 and B7-2, respectively). As used herein, the term "CTLA-4" includes human CTLA-4 (hCTLA-4), variants, isoforms and species homologs of hCTLA-4 and analogs that share at least one common epitope with hCTLA-4. The complete hCTLA-4 sequence can be found under GenBank Accession No. AAB59385.

[0098] The term "immunotherapy" refers to the treatment of a subject having, at risk of recurring, or having a recurrence of a disease by methods that involve eliciting, enhancing, suppressing, or otherwise modifying the immune response. "Treatment" or "treatment" of a subject refers to any type of intervention or procedure or administration of an active agent to a subject with the goal of ameliorating, alleviating, ameliorating, arresting, delaying, or preventing the onset, progression, occurrence, severity, or recurrence of symptoms, complications, conditions, or biochemical manifestations associated with a disease.

[0099] As used herein, "PD-L1 positive" may be used interchangeably with "at least about 1% PD-L1 expression." In one embodiment, PD-L1 expression may be measured by any method known in the art. In another embodiment, PD-L1 expression is measured by automated IHC. A PD-L1 positive tumor may have at least about 1%, at least about 2%, at least about 5%, at least about 10%, at least about 20%, at least about 25%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% of tumor cells expressing PD-L1, as measured by automated IHC. In one embodiment, "PD-L1 positive" means that there are at least 100 cells that express PD-L1 on the cell surface. In another embodiment, "PD-L2 positive" means that there are at least 100 cells that express PD-L2 on their cell surface.

[0100] "Programmed Death-1" (PD-1) refers to an immunoinhibitory receptor that belongs to the CD28 family. PD-1 is found primarily on activated T cells in vivo and binds to two ligands, PD-L1 and PD-L2. As used herein, the term "PD-1" includes human PD-1 (hPD-1), variants, isoforms and species homologs of hPD-1 and analogs that share at least one epitope in common with hPD-1. The complete hPD-1 sequence can be found in GenBank Accession No. U64863.

[0101] "Programmed death-ligand-1" (PD-L1) is one of two cell surface glycoprotein ligands for PD-1 (the other is PD-L2) that downregulates T cell activation and cytokine secretion upon binding to PD-1. As used herein, the term "PD-L1" includes human PD-L1 (hPD-L1), variants, isoforms and species homologs of hPD-L1 and analogs that share at least one epitope in common with hPD-L1. The complete hPD-L1 sequence can be found under GenBank Accession No. Q9NZQ7.

[0102] A "subject" includes any human or non-human animal. The term "non-human animal" includes, but is not limited to, vertebrates such as non-human primates, sheep, dogs, and rodents such as mice, rats, and guinea pigs. In some embodiments, the subject is a human. The terms "subject" and "patient" are used interchangeably herein.

[0103] A "therapeutically effective amount" or "therapeutically effective dose" of a drug or therapeutic agent is any amount of drug that, when used alone or in combination with other therapeutic agents, protects a subject against disease onset or promotes disease regression, as evidenced by a reduction in the severity of disease symptoms, an increase in the frequency and duration of disease-free periods, or prevention of functional impairment or disability due to disease morbidity. The ability of a therapeutic agent to promote disease regression can be assessed using a variety of methods known to those of skill in the art, such as by assaying the activity of the agent in human subjects during clinical trials, in animal model systems predictive of efficacy in humans, or in in vitro assays.

[0104] As used herein, a "sub-therapeutic dose" refers to a dose of a therapeutic compound (e.g., an antibody) that is lower than the usual or typical dose of that therapeutic compound when used alone to treat a hyperproliferative disease (e.g., cancer).

[0105] As an example, an "anti-cancer agent" promotes cancer regression or prevents further tumor growth in a subject. In some embodiments, a therapeutically effective amount of the drug promotes cancer regression to the point of eliminating the cancer. "Promoting cancer regression" means that administration of an effective amount of the drug, alone or in combination with an anti-neoplastic agent, results in a decrease in tumor growth or size, tumor necrosis, a decrease in the severity of at least one disease symptom, an increase in the frequency and duration of disease-free periods, or prevention of functional impairment or disability due to disease morbidity. Furthermore, the terms "effective" and "efficacy" in relation to treatment include both pharmacological effectiveness and physiological safety. Pharmacological effectiveness refers to the ability of a drug to promote cancer regression in a patient. Physiological safety refers to the level of toxicity or other adverse physiological effects (adverse effects) at the cell, organ and / or organism level resulting from drug administration.

[0106] As an example of tumor treatment, a therapeutically effective amount of an anti-cancer agent can inhibit cell proliferation or tumor growth by at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, or at least about 100% relative to an untreated subject. In other embodiments of the invention, tumor regression can be observed and continued for a period of at least about 20 days, at least about 30 days, at least about 40 days, at least about 50 days, or at least about 60 days. Even with these final assessments of therapeutic efficacy, the evaluation of immunotherapeutic agents must also take into account "immune-related response patterns."

[0107] "Immune-related response pattern" refers to a clinical response pattern frequently observed in cancer patients treated with immunotherapeutic agents that produce antitumor effects by inducing a cancer-specific immune response or by modulating innate immune processes. This response pattern, in the evaluation of conventional chemotherapeutic agents, is classified as disease progression, which is synonymous with drug failure, and is characterized by an initial increase in tumor burden or the appearance of new lesions followed by a beneficial therapeutic effect. Thus, proper evaluation of immunotherapeutic agents may require long-term monitoring of the effects of these agents on the target disease.

[0108] A therapeutically effective amount of a drug includes any amount of drug that, when administered alone or in combination with an anti-neoplastic agent to a subject at risk of developing cancer (e.g., a subject with a pre-malignant condition) or having a recurrence of cancer, prevents the onset or recurrence of cancer, i.e., a "prophylactically effective amount." In some embodiments, a prophylactically effective amount completely prevents the onset or recurrence of cancer. "Preventing" the onset or recurrence of cancer means reducing the likelihood of cancer onset or recurrence or completely preventing the onset or recurrence of cancer.

[0109] As used herein, the term "weight-based dose" means that the dose administered to a patient is calculated based on the patient's weight. For example, if a patient weighing 60 kg requires 3 mg / kg of anti-PD-1 antibody, the appropriate amount of anti-PD-1 antibody for administration (i.e., 180 mg) can be calculated and used.

[0110] The use of the term "fixed dose" with respect to the methods of the invention means that two or more different antibodies (e.g., an anti-PD-1 antibody and an anti-CTLA-4 antibody) in a single composition are present in the composition in a specific (fixed) ratio to each other. In certain embodiments, the fixed dose is based on the weight (e.g., mg) of the antibody. In certain embodiments, the fixed dose is based on the concentration (e.g., mg / ml) of the antibody. In certain embodiments, the ratio is at least about 1:1, about 1:2, about 1:3, about 1:4, about 1:5, about 1:6, about 1:7, about 1:8, about 1:9, about 1:10, about 1:15, about 1:20, about 1:30, about 1:40, about 1:50, about 1:60, about 1:70, about 1:80, about 1:90, about 1:100, about 1:120, about 1:140, about 1:160, about 1:180, about 1:200, about 1:200:1, about 1:200:2, about 1:200:3, about 1:200:4, about 1:200:5, about 1:300:6, about 1:400:7, about 1:500:8, about 1:600:9, about 1:700:1, about 1:800:1, about 1:1000, about 1:1200, about 1:1400, about 1:1600, about 1:18 ... 1, about 160:1, about 140:1, about 120:1, about 100:1, about 90:1, about 80:1, about 70:1, about 60:1, about 50:1, about 40:1, about 30:1, about 20:1, about 15:1, about 10:1, about 9:1, about 8:1, about 7:1, about 6:1, about 5:1, about 4:1, about 3:1 or about 2:1 mg of first antibody (e.g., anti-PD-1 antibody) to mg of second antibody (e.g., anti-CTLA-4 antibody). For example, a 3:1 ratio of anti-PD-1 antibody to anti-CTLA-4 antibody can mean that a vial can contain about 240 mg of anti-PD-1 antibody and 80 mg of anti-CTLA-4 antibody or about 3 mg / ml of anti-PD-1 antibody and 1 mg / ml of anti-CTLA-4 antibody.

[0111] The use of the term "flat dose" in relation to the methods and dosages of the present invention refers to a dose administered to a patient regardless of the patient's weight or body surface area (BSA). Thus, a flat dose is provided as an absolute amount of agent (e.g., anti-CTLA-4 antibody and / or anti-PD-1 antibody) rather than as a mg / kg dose. For example, a 60 kg human and a 100 kg human would receive the same dose of antibody (e.g., 240 mg of anti-PD-1 antibody).

[0112] The use of the alternative (e.g., "or") should be construed to mean either one, both, or any combination thereof. As used herein, the singular forms "a," "an," and "the" should be construed to refer to "one or more" of any referenced or listed components.

[0113] The term "about" or "essentially includes" refers to a value or composition that is within an acceptable error range of a particular value or composition as determined by one of ordinary skill in the art, which depends in part on how the value or composition is measured or determined, i.e., the limitations of the measurement system. For example, "about" or "essentially includes" can mean within 1 or more than 1 standard deviation according to the practice of the art. Alternatively, "about" or "essentially includes" can mean within a range of up to 10% or 20% (i.e., ±10% or ±20%). For example, about 3 mg can include any number between 2.7 mg and 3.3 mg (for 10%) or any number between 2.4 mg and 3.6 mg (for 20%). Furthermore, particularly with respect to biological systems or processes, the term can mean up to an order of magnitude or up to 5 times the value. When a particular value or composition is provided in the specification and claims, unless otherwise indicated, the meaning of "about" or "essentially includes" should be assumed to be within an acceptable error range for that particular value or composition.

[0114] As used herein, the term "about once a week," "about once every two weeks," or any other similar dosing interval means an approximate number. "About once a week" can include every 7 days ± 1 day, i.e., every 6 days to every 8 days. "About once every two weeks" can include every 14 days ± 3 days, i.e., every 11 days to every 17 days. Similar approximations apply, for example, to about once every 3 weeks, about once every 4 weeks, about once every 5 weeks, about once every 6 weeks, and about once every 12 weeks. In certain embodiments, a dosing interval of about once every 6 weeks or about once every 12 weeks means that the first administration can be administered on any day of the first week, and then the next administration can be administered on any day of the sixth or twelfth week, respectively. In other embodiments, a dosing interval of about once every 6 weeks or about once every 12 weeks means that the first dose is administered on a particular day of the week (e.g., Monday) in the first week, and then the next dose is administered on a particular day of the week (i.e., Monday) in the sixth or twelfth week, respectively.

[0115] Unless otherwise specified, any concentration range, percentage range, ratio range, or integer range set forth herein should be interpreted to include every integer value within the stated range and fractions thereof, where appropriate (e.g., 1 / 10 and 1 / 100 of an integer).

[0116] Various aspects of the invention are described in further detail in the following subsections.

[0117] Methods of the Invention The present invention provides a method of treating a subject having a tumor derived from SCLC, the method comprising administering to the subject an antibody or antigen-binding portion thereof that specifically binds to the programmed death-1 (PD-1) receptor and inhibits PD-1 activity (an "anti-PD-1 antibody"). The present invention further provides a method of treating a subject having a tumor derived from SCLC, the method comprising administering to the subject a combination of (a) an antibody or antigen-binding portion thereof that specifically binds to the PD-1 receptor and inhibits PD-1 activity (an "anti-PD-1 antibody"); and (b) an antibody or antigen-binding portion thereof that specifically binds to cytotoxic T-lymphocyte antigen-4 (CTLA-4) and inhibits CTLA-4 activity (an "anti-CTLA-4 antibody"). In certain embodiments, the subject is a human patient.

[0118] In certain embodiments, the subject is a chemotherapy-naive patient (e.g., a patient who has not previously received any chemotherapy). In other embodiments, the subject has received other cancer treatments (e.g., chemotherapy), but is resistant or refractory to such other cancer treatments. In certain embodiments, the SCLC is recurrent SCLC. In certain embodiments, the subject has received at least one, at least two, at least three, at least four, or at least five prior lines of therapy to treat the tumor. In certain embodiments, the subject has received one prior line of therapy to treat the tumor. In other embodiments, the subject has received two prior lines of therapy to treat the tumor. In other embodiments, the subject has received three prior lines of therapy to treat the tumor. In other embodiments, the subject has received four prior lines of therapy to treat the tumor. In other embodiments, the subject has received five prior lines of therapy to treat the tumor. In other embodiments, the subject has received more than five prior lines of therapy to treat the tumor.

[0119] In some embodiments, the prior line of therapy includes a chemotherapeutic agent. In some embodiments, the chemotherapeutic agent includes a platinum-based therapy. In some embodiments, the platinum-based therapy includes a platinum-based anti-neoplastic agent selected from the group consisting of cisplatin, carboplatin, oxaliplatin, nedaplatin, triplatin tetranitrate, phenanthriplatin, picoplatin, satraplatin, and any combination thereof. In certain embodiments, the platinum-based therapy includes cisplatin (e.g., cisplatin in combination with etoposide). In some embodiments, the subject has received prior radiation therapy. In other embodiments, the prior therapy includes an antibody therapy.

[0120] In certain embodiments, the subject has cancer cells that express mutated forms of EGFR or KRAS genes. In some embodiments, the subject has cancer cells that are PD-L1 positive. In some embodiments, the subject has cancer cells that are PD-L1 negative. In some embodiments, the subject has never smoked. In some embodiments, the subject is a former smoker. In some embodiments, the subject is a current smoker. In some embodiments, the SCLC comprises small cell carcinoma. In some embodiments, the SCLC comprises combined small cell carcinoma.

[0121] In certain embodiments, the method comprises administering an effective amount of an anti-PD-1 antibody or administering an effective amount of an anti-PD-L1 antibody and an effective amount of an anti-CTLA-4 antibody. The effective amounts of the anti-PD-1 antibody and / or anti-CTLA-4 antibody may be a flat dose or a weight-based dose.

[0122] In one embodiment, the invention includes a method of treating cancer or a subject with cancer, comprising administering an anti-PD-1 antagonist and an anti-CD30 antibody in combination to treat the cancer. As used herein, an "anti-PD-1 antagonist" includes any molecule that inhibits the interaction of PD-1 (the receptor) and PD-L1 (the ligand), such that the PD-1 / PD-L1 signaling pathway is blocked. In another embodiment, the anti-PD-1 antagonist is a PD-1-Fc fusion protein. In one embodiment, the anti-PD-1 antagonist includes an anti-PD-1 fusion protein, an antisense molecule, a small molecule, a ribozyme, or a nanobody that inhibits or blocks the interaction of PD-1 and PD-L1.

[0123] In certain embodiments, the treatment of the invention (e.g., administration of an anti-PD-1 antibody or administration of an anti-PD-1 antibody and an anti-CTLA-4 antibody) effectively extends the survival of the subject. In certain embodiments, the anti-PD-1 antibody or anti-PD-1 antibody and anti-CTLA-4 antibody combination treatment of the invention extends the progression-free survival of the subject. In certain embodiments, the anti-PD-1 antibody or anti-PD-1 antibody and anti-CTLA-4 antibody combination treatment of the invention extends the progression-free survival of the subject compared to standard of care treatments. In certain embodiments, the anti-PD-1 antibody and anti-CTLA-4 antibody combination treatment of the invention extends the progression-free survival of the subject compared to anti-PD-1 antibody alone (i.e., anti-PD-1 antibody monotherapy). In certain embodiments, the anti-PD-1 antibody and anti-CTLA-4 antibody combination treatment of the invention extends the progression-free survival of the subject compared to other anti-PD-1 antibody combinations.

[0124] In certain embodiments, after administration of an anti-PD-1 antibody or an anti-PD-1 antibody and an anti-CTLA-4 antibody, a subject having a tumor derived from SCLC may exhibit an overall survival of at least about 2 months, at least about 3 months, at least about 4 months, at least about 5 months, at least about 6 months, at least about 7 months, at least about 8 months, at least about 9 months, at least about 10 months, at least about 11 months, at least about 12 months, at least about 13 months, at least about 14 months at least about 15 months, at least about 16 months, at least about 17 months, at least about 18 months, at least about 19 months, at least about 20 months, at least about 21 months, at least about 22 months, at least about 23 months, at least about 2 years, at least about 3 years, at least about 4 years, or at least about 5 years.

[0125] In other embodiments, following administration of a therapy of the invention (e.g., an anti-PD-1 antibody therapy or an anti-PD-1 antibody and an anti-CTLA-4 antibody therapy), the survival or overall survival of a subject is extended by at least about 1 month, at least about 2 months, at least about 3 months, at least about 4 months, at least about 6 months, or at least about 1 year, as compared to other subjects treated with a standard of care therapy (e.g., a platinum-based chemotherapy agent) alone or with a different administration schedule of the therapy. For example, the survival or overall survival of a subject treated with an anti-PD-1 antibody disclosed herein is extended by at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 40%, at least about 50%, or at least about 75%, as compared to other subjects treated with a standard of care therapy (e.g., a platinum-based chemotherapy agent) alone or with a different administration schedule of the anti-PD-1 antibody therapy.

[0126] In other embodiments, after administration of a combination therapy comprising an anti-PD-1 antibody and an anti-CTLA-4 antibody, the subject's survival or overall survival is extended by at least about 1 month, at least about 2 months, at least about 3 months, at least about 4 months, at least about 6 months, or at least about 1 year, as compared to other subjects treated with a standard of care treatment (e.g., a platinum-based chemotherapy agent) alone, an anti-PD-1 antibody alone, or a different dosing schedule of the combination therapy. For example, the survival or overall survival of a subject treated with an anti-PD-1 antibody and anti-CTLA-4 antibody combination therapy disclosed herein is extended by at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 40%, at least about 50%, or at least about 75%, as compared to other subjects treated with a standard of care treatment (e.g., a platinum-based chemotherapy agent) alone, an anti-PD-1 antibody alone, or a different dosing schedule of the combination therapy.

[0127] In some embodiments, the treatment of the present invention effectively extends the progression-free survival of the subject.In some embodiments, the subject shows at least about 1 month, at least about 2 months, at least about 3 months, at least about 4 months, at least about 5 months, at least about 6 months, at least about 7 months, at least about 8 months, at least about 9 months, at least about 10 months, at least about 11 months, at least about 1 year, at least about 18 months, at least about 2 years, at least about 3 years, at least about 4 years or at least about 5 years of progression-free survival.

[0128] In some embodiments, the anti-PD-1 and anti-CTLA-4 antibodies are formulated for intravenous administration. In some embodiments, the anti-PD-1 and anti-CTLA-4 antibodies are administered sequentially. In some embodiments, the anti-PD-1 and anti-CTLA-4 antibodies are administered within 30 minutes of each other. In some embodiments, the anti-PD-1 antibody is administered before the anti-CTLA-4 antibody. In other embodiments, the anti-CTLA-4 antibody is administered before the anti-PD-1 antibody. In other embodiments, the anti-PD-1 and anti-CTLA-4 antibodies are administered simultaneously in separate compositions. In further embodiments, the anti-PD-1 and anti-CTLA-4 antibodies are mixed as a single composition for simultaneous administration.

[0129] In certain embodiments, the anti-PD-1 antibody and the anti-CTLA-4 antibody are administered as a fixed dose.

[0130] In some embodiments, the PD-L1 status of the tumor in the subject is measured before administration of any composition or use of any method described herein. In some embodiments, the PD-L1 expression level of the tumor is at least about 1%, at least about 2%, at least about 3%, at least about 4%, at least about 5%, at least about 6%, at least about 7%, at least about 8%, at least about 9%, at least about 10%, at least about 11%, at least about 12%, at least about 13%, at least about 14%, at least about 15%, at least about 20% or more than at least about 20%. In other embodiments, the PD-L1 status of the tumor is at least about 1%. In other embodiments, the PD-L1 status of the subject is at least about 5%. In some embodiments, the PD-L1 status of the tumor is at least about 10%.

[0131] In certain embodiments, the median progression-free survival of subjects with tumors having ≧1% PD-L1 expression is at least about 1 week, at least about 2 weeks, at least about 3 weeks, at least about 4 weeks, at least about 1 month, at least about 2 months, at least about 3 months, at least about 4 months, at least about 5 months, at least about 6 months, at least about 7 months, at least about 8 months, at least about 9 months, at least about 10 months, at least about 11 months, or at least about 1 year longer than the median progression-free survival of subjects with tumors having <1% PD-L1 expression. In certain embodiments, the progression-free survival of subjects with a tumor having ≧1% PD-L1 expression is at least about 1 month, at least about 2 months, at least about 3 months, at least about 4 months, at least about 5 months, at least about 6 months, at least about 7 months, at least about 8 months, at least about 9 months, at least about 10 months, at least about 11 months, at least about 1 year, at least about 18 months, at least about 2 years, at least about 3 years, at least about 4 years, or at least about 5 years.

[0132] To assess PD-L1 expression, in certain embodiments, a test tissue sample can be obtained from a patient in need of treatment. In other embodiments, assessing PD-L1 expression can be accomplished without obtaining a test tissue sample. In certain embodiments, selecting a suitable patient includes (i) providing a test tissue sample, optionally obtained from a tissue of a patient having cancer, the test tissue sample comprising tumor cells and / or tumor infiltrating inflammatory cells; and (ii) assessing the proportion of cells in the test tissue sample that express PD-L1 on their cell surface based on the proportion of cells in the test tissue sample that express PD-L1 on their cell surface being higher than a predetermined threshold level.

[0133] In any of the methods involving measuring, however, it should be understood that the step involving providing a test tissue sample obtained from a patient is an optional step. In certain embodiments, it should be understood that the "measuring" or "assessing" step to identify or determine the number or proportion of cells expressing PD-L1 on their cell surface in the test tissue sample is performed by a transformation method to assay for PD-L1 expression, for example, by performing a reverse transcriptase-polymerase chain reaction (RT-PCR) assay or an IHC assay. In certain other embodiments, no transformation method steps are included, and PD-L1 expression is assessed, for example, by reviewing a test result report from a laboratory. In certain embodiments, the method steps up to and including the assessment of PD-L1 expression provide an intermediate result that can be provided to a physician or other medical professional for use in selecting suitable candidates for anti-PD-1 antibodies or anti-PD-L1 antibody therapy. In certain embodiments, the step of providing the intermediate report is performed by a physician or someone working under the direction of a physician. In other embodiments, these steps are performed in an independent laboratory or by an independent person, such as a laboratory technician.

[0134] In certain embodiments of any of the methods, the proportion of cells expressing PD-L1 is assessed by performing an assay to determine the presence of PD-L1 RNA. In further embodiments, the presence of PD-L1 RNA is determined by RT-PCR, in situ hybridization, or RNase protection. In other embodiments, the proportion of cells expressing PD-L1 is assessed by performing an assay to determine the presence of a PD-L1 polypeptide. In further embodiments, the presence of a PD-L1 polypeptide is determined by immunohistochemistry (IHC), enzyme-linked immunosorbent assay (ELISA), in vivo imaging, or flow cytometry. In certain embodiments, PD-L1 expression is assayed by IHC. In other embodiments of all of these methods, cell surface expression of PD-L1 is assayed using, for example, IHC or in vivo imaging.

[0135] Imaging techniques have provided important tools in cancer research and treatment. Recent developments in molecular imaging systems, including positron emission tomography (PET), single photon emission computed tomography (SPECT), fluorescence imaging (FRI), fluorescence mediated tomography (FMT), bioluminescence imaging (BLI), confocal laser scanning microscopy (LSCM) and multiphoton microscopy (MPM), may usher in a wider use of these techniques in cancer research. Some of these molecular imaging systems allow physicians not only to see where tumors are in the body, but also to visualize the expression and activity of specific molecules, cells and biological processes that affect tumor behavior and / or response to therapeutic agents (Condeelis and Weissleder, "In vivo imaging in cancer," Cold Spring Harb. Perspect. Biol. 2(12):a003848 (2010)). Antibody specificity combined with the sensitivity and resolution of PET makes immunoPET imaging particularly attractive for monitoring and assaying antigen expression in tissue samples (McCabe and Wu, "Positive progress in immunoPET-not just a coincidence," Cancer Biother. Radiopharm. 25(3):253-61 (2010); Olafsen et al., "ImmunoPET imaging of B-cell lymphoma using 124I-anti-CD20 scFv dimers (diabodies)," Protein Eng. Des. Sel. 23(4):243-9 (2010)). In certain embodiments of any of the methods, PD-L1 expression is assayed by immunoPET imaging. In certain embodiments of any of the methods, the percentage of cells expressing PD-L1 in the test tissue sample is assessed by performing an assay to determine the presence of cell surface PD-L1 polypeptide in the test tissue sample. In certain embodiments, the test tissue sample is a FFPE tissue sample. In other embodiments, the presence of a PD-L1 polypeptide is determined by an IHC assay.In a further embodiment, the IHC assay is performed by an automated process. In one embodiment, the IHC assay is performed using an anti-PD-L1 monoclonal antibody that binds to a PD-L1 polypeptide.

[0136] In one embodiment of the method, an automated IHC method is used to assay the expression of cell surface PD-L1 in an FFPE tissue specimen. The present invention provides a method for detecting the presence of human PD-L1 antigen in a test tissue sample or quantifying the level of human PD-L1 antigen or the percentage of cells in the sample expressing the antigen, the method comprising contacting the test sample and a negative control sample with a monoclonal antibody that specifically binds to human PD-L1 under conditions that allow the formation of a complex between the antibody or a portion thereof and human PD-L1. In one embodiment, the test and control tissue samples are FFPE samples. Complex formation is then detected, where a difference in complex formation between the test sample and the negative control sample is indicative of the presence of human PD-L1 antigen in the sample. Various methods are used to quantify PD-L1 expression.

[0137] In certain embodiments, the automated IHC method includes (a) deparaffinizing and rehydrating tissue sections mounted in an autostainer, (b) heating at 110°C for 10 minutes using a decloaking chamber and pH 6 buffer to retrieve antigens, (c) loading reagents into the autostainer, and (d) running the autostainer to include the steps of neutralizing endogenous peroxidase in the tissue specimen; blocking nonspecific protein binding sites on the slide; incubating the slide with primary antibody; incubating with post-primary blocking agent; incubating with NovoLink polymer; adding chromogen substrate and developing; and counterstaining with hematoxylin.

[0138] To assess PD-L1 expression in tumor tissue samples, pathologists performed membrane PD-L1 staining in each microscopic field. +The number of tumor cells is examined, and the percentage of cells that are thought to be positive is estimated, and then normalized to obtain a final percentage. Different staining intensities are defined as 0 / negative, 1+ / weak, 2+ / moderate, and 3+ / strong. In general, percentage values ​​are first assigned to 0 and 3+ buckets, and then the intermediate 1+ and 2+ intensities are considered. For highly heterogeneous tissues, the specimen is divided into zones, and each zone is scored separately, and then combined into one set of percentage values. The percentage of negative and positive cells of different staining intensities is determined from each region, and the median value is assigned to each zone. A final percentage value is assigned to the tissue for each staining intensity category of negative, 1+, 2+, and 3+. The composite of all staining intensities should be 100%. In some embodiments, the threshold number of cells required to be PD-L1 positive is at least about 100, at least about 125, at least about 150, at least about 175, or at least about 200 cells. In one embodiment, the threshold number of cells required to be PD-L1 positive is at least about 100 cells.

[0139] Staining is also evaluated in tumor infiltrating inflammatory cells such as macrophages and lymphocytes. In most cases, macrophages serve as an internal positive control since staining is observed in the majority of macrophages. Although it is not necessary to stain with 3+ intensity, lack of staining of macrophages should be considered to exclude any technical failure. Macrophages and lymphocytes are evaluated for plasma membrane staining and scored for all samples only as positive or negative for each cell category. Staining is also characterized by an outside / inside tumor immune cell designation. "Inside" means that the immune cells are on the tumor area border without physical interposition within the tumor tissue and / or between tumor cells. "Outside" means that there is no physical association with the tumor and the immune cells are found in the periphery associated with the connecting tissue or any associated adjacent tissue.

[0140] In some embodiments of these scoring methods, samples are scored by two pathologists working independently, and the scores are then fixed. In some other embodiments, the identification of positive and negative cells is scored using appropriate software.

[0141] The histoscore is used as a more quantitative measure of the IHC data. The histoscore is calculated as follows: Histoscore = [(%Tumor x 1 (low intensity)) + (%Tumor x 2 (medium intensity)) + (%Tumor x 3 (high intensity)]

[0142] To determine the Histoscore, a pathologist estimates the percentage of staining cells in each intensity category within a specimen. Because expression of most biomarkers is heterogeneous, the Histoscore is a true representation of overall expression. Final Histoscore ranges from 0 (no expression) to 300 (maximal expression).

[0143] Another means of quantifying PD-L1 expression in test tissue sample IHC is the determination of the adapted inflammation score (AIS), a score defined as the density of inflammation multiplied by the percent of PD-L1 expression by tumor-infiltrating inflammatory cells (Taube et al., "Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape," Sci. Transl. Med. 4(127):127ra37 (2012)).

[0144] The method can treat tumors derived from SCLC at any stage. For SCLC, the present invention can be used in the following stages: occult (hidden; TX, N0 and M0), stage 0 (intraepithelial carcinoma; Tis, N0 and M0), stage IA (T1a / T1b, N0 and M0), stage IB (T2a, N0, M0), stage IIA (T1a / T1b, N1 and M0; T2a, N1 and M0; or T2b, N0 and M0), stage IIB (T2b, N1 and M0; or T3, N0, M0), stage IIIA (T1-T3, N2 and M0; T3, N1 and M0; or T4, N0-N0), stage IV (T2b, N1 and M0; or T3, N0, M0), stage IIIB (T2b, N1 and M0; or T4, N0-N0), stage IV (T1a / T1b, N1 and M0; or T3 ... At least nine stages are used: stage IIIB (any T, N3, M0; or T4, N2, and M0), stage IIIB (any T, any N, and M1a; or any T, any N, and M1b) (see, e.g., http: / / www.cancer.org / cancer / lungcancer-smallcell / detailedguide / small-cell-lung-cancer-staging, last accessed June 2, 2016). In the occult stage, the cancer cannot be seen by imaging or bronchoscopy. In stage 0, cancer cells are found in the lining of the airways.

[0145] In one embodiment, this method treats stage I SCLC. Stage I SCLC is divided into stage IA and stage IB. In stage IA, tumor diameter is not larger than 3cm, does not reach the membrane surrounding the lung, does not affect the main branch of the bronchus, and does not spread to lymph nodes or distant sites. In stage IB, one or more of the following applies: 1) tumor is larger than 3cm but not larger than 5cm; 2) cancer spreads to the main bronchus, but not within 2cm of the carina; 3) tumor grows in the visceral pleura (membrane surrounding the lung) and is not larger than 5cm; or 4) tumor partially obstructs airway (and is not larger than 5cm).

[0146] In another embodiment, the method of the present invention treats stage II SCLC. Stage II SCLC is divided into stages IIA and IIB. In stage IIA, cancer has spread to the lungs and / or lymph nodes (hilar lymph nodes) in the area surrounding the area where the bronchi enter the lungs. If cancer has spread to lymph nodes, it can only spread to lymph nodes on the same side of the chest as the tumor. If cancer has not spread to lymph nodes, cancer has spread to the area where the bronchi enter the lungs, and if one or more of the following is true, the cancer is stage IIA: 1) the tumor is larger than 3 cm, but not larger than 5 cm; 2) the tumor has grown into the main bronchus, but not within 2 cm of the carina (and not larger than 5 cm); 3) the tumor has grown into the visceral pleura (the membrane that surrounds the lungs) and is not larger than 5 cm; or 4) the tumor partially obstructs the airway (and not larger than 5 cm). A tumor is considered stage IIA if the cancer has not spread to the lymph nodes and one or more of the following is true: 1) the tumor is larger than 5 cm but not larger than 7 cm; 2) the cancer has spread to the main bronchi and is at least 2 cm away from the location of the carina; 3) the tumor has spread to the visceral pleura (the membrane that surrounds the lungs); or 4) the tumor partially obstructs an airway (and is between 5 and 7 cm in diameter). In stage IIB, the cancer may or may not have spread to the lymph nodes. If the cancer has spread to lymph nodes, it can only spread to lymph nodes on the same side of the chest as the tumor, and the lymph nodes that have cancer are in the lung or near the bronchi and one or more of the following is true: 1) the tumor is larger than 5 cm but not larger than 7 cm; 2) the tumor has spread to the main bronchus and is at least 2 cm from the location of the carina; 3) the tumor has spread to the visceral pleura (the membrane that surrounds the lungs) and is 5-7 cm in diameter; or 4) the cancer partially obstructs the airway (and is 5-7 cm in diameter).A tumor is considered stage IIB if cancer has not spread to lymph nodes and one or more of the following is true: 1) the tumor is larger than 7 cm; 2) cancer has grown into the chest wall, the respiratory muscles that separate the chest from the abdomen (diaphragm), the membrane that lines the space between the lungs (mediastinal pleura), or the membrane of the sac that surrounds the heart (parietal pericardium); 3) cancer has invaded a main bronchus and is closer than 2 cm (about 3 / 4 inch) to the carina, but does not involve the carina itself; 4) cancer has grown far enough into the airways to cause collapse of the entire lung or to cause pneumonia in the entire lung; or 5) two or more separate tumor nodules are present in the same lobe of the lung.

[0147] In other embodiments, any of the methods of the present invention treat stage III SCLC, including stage IIIA and / or stage IIIB. Stage IIIA is divided into three sections. These three sections are based on 1) the size of the tumor; 2) where the tumor is found; and 3) which (if any) lymph nodes have cancer. In the first type of stage IIIA SCLC, the main tumor can be of any size and has not grown in the space between the lungs (mediastinum), the heart, the large blood vessels near the heart (e.g., aorta), the windpipe (trachea), the tube that connects the throat to the stomach (esophagus), the spine, or the carina of the trachea, nor has it spread to different lobes of the same lung. In addition, the cancer has spread to lymph nodes around the carina (the point where the bronchus divides into the right and left bronchi) or in the space between the lungs (mediastinum), and these lymph nodes are on the same side as the main lung tumor, but the cancer has not spread to distant sites. In the second type of stage IIIA SCLC, cancer has spread to lymph nodes on the same side of the chest as the tumor, and the cancer-bearing lymph nodes are within the lung or near the bronchi, and: 1) the tumor is larger than 7 cm in diameter; 2) cancer has grown into the chest wall, the respiratory muscle that separates the chest from the abdomen (diaphragm), the membrane that lines the space between the lungs (mediastinal pleura), or the membrane of the sac that surrounds the heart (parietal pericardium); 3) cancer has invaded the main bronchus and is closer than 2 cm to the carina but does not involve the carina itself; 4) two or more separate tumor nodules are present in the same lobe of the lung; and 5) cancer has grown far enough into the airways to cause collapse of the entire lung or to cause pneumonia in the entire lung. In the third type of stage IIIA SCLC, cancer may or may not have spread within the lungs and / or to lymph nodes around the area where the bronchi enter the lungs (hilar lymph nodes), and one or more of the following is true: 1) a tumor of any size has grown in the space between the lungs (mediastinum), the heart, the large blood vessels near the heart (such as the aorta), the windpipe (trachea), the tube that connects the throat to the stomach (esophagus), the spine, or the tracheal bifurcation; and / or 2) two or more separate tumor nodules are in different lobes of the same lung.

[0148] Stage IIIB is divided into two sections based on 1) the size of the tumor, 2) where the tumor is found, and 3) which lymph nodes have cancer. In the first type of stage IIIB SCLC, the cancer may be of any size; it may or may not have grown into nearby structures or caused pneumonia or lung collapse; and has spread to lymph nodes close to the clavicle on either side and / or to lymph nodes at the hilum or mediastinal on the opposite side to the primary tumor. However, the cancer has not spread to distal sites. In the second type of stage IIIB SCLC, the cancer has also spread to lymph nodes around the carina (the point where the bronchi divide into the right and left bronchi) or in the space between the lungs (mediastinum). The affected lymph nodes are on the same side as the main lung tumor. It has not spread to distal sites. In addition, one or more of the following are true: 1) a tumor of any size is growing in the space between the lungs (mediastinum), the heart, the large blood vessels near the heart (e.g., the aorta), the windpipe (trachea), the tube that connects the throat to the stomach (esophagus), the spine, or the carina of the trachea; and / or 2) two or more separate tumor nodules are present in different lobes of the same lung.

[0149] In one embodiment, the method of the present invention treats stage IV SCLC. Stage IV SCLC is divided into two types. In the first type of stage IV SCLC, tumor can be any size, and one or more of the following applies: 1) there is one or more tumors in both lungs; 2) cancer is found in the lung or in the fluid around the heart. In the second type of stage IV SCLC, cancer can be any size, and may or may not grow into nearby structures, may or may not reach nearby lymph nodes, and may or may not spread to distant lymph nodes or organs such as liver, bone or brain.

[0150] Anti-PD-1 or anti-PD-L1 antibodies Anti-PD-1 antibodies suitable for use in the methods of the invention are those that bind to PD-1 with high specificity and affinity, block PD-L1 binding, and inhibit the immunosuppressive effects of the PD-1 signaling pathway. In any of the therapeutic methods described herein, an anti-PD-1 or anti-PD-L1 "antibody" comprises an antigen-binding portion that binds to the PD-1 or PD-L1 receptor, respectively, and exhibits functional properties similar to whole antibodies in ligand binding inhibition and immune system upregulation. In one embodiment, the anti-PD-1 antibody or antigen-binding portion thereof cross-competes with nivolumab for binding to human PD-1. In other embodiments, the anti-PD-L1 antibody or antigen-binding fragment thereof competes with BMS-936559, MPDL3280A, MEDI4736, or MSB0010718C for binding to human PD-L1.

[0151] In other embodiments, the anti-PD-1 antibody or anti-PD-L1 antibody, or antigen-binding portion thereof, is a chimeric, humanized, or human monoclonal antibody, or portion thereof. In certain embodiments for treating a human subject, the antibody is a humanized antibody. In other embodiments for treating a human subject, the antibody is a human antibody. Antibodies of the IgG1, IgG2, IgG3, or IgG4 isotype may be used.

[0152] In certain embodiments, the anti-PD-1 or anti-PD-L1 antibody, or antigen-binding portion thereof, comprises a heavy chain constant region that is of a human IgG1 or IgG4 isotype. In certain other embodiments, the sequence of the IgG4 heavy chain constant region of the anti-PD-1 or anti-PD-L1 antibody, or antigen-binding portion thereof, comprises a S228P mutation, which replaces a serine residue in the hinge region with a proline residue normally found at the corresponding position in IgG1 isotype antibodies. This mutation, present in nivolumab, prevents Fab arm exchange with endogenous IgG4 antibodies while maintaining the low affinity for Fc receptor activation associated with wild-type IgG4 antibodies (Wang et al. In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates, Cancer Imm Res, 2(9):846-56 (2014)). In yet other embodiments, the antibody comprises a light chain constant region that is a human kappa or lambda constant region. In other embodiments, the anti-PD-1 antibody, anti-PD-L1 antibody, or antigen-binding portion thereof, is a monoclonal antibody, or antigen-binding portion thereof.

[0153] Human antibodies that specifically bind to PD-1 with high affinity are disclosed in U.S. Patent 8,008,449. Other anti-PD-1 monoclonal antibodies are described, for example, in U.S. Patents 6,808,710, 7,488,802, 8,168,757, and 8,354,509, and PCT Publication WO 2012 / 145493. Each of the anti-PD-1 human antibodies disclosed in U.S. Patent 8,008,449 has been shown to exhibit one or more of the following properties: (a) a specific binding affinity of 1×10 to human PD-1 as determined by surface plasmon resonance using a Biacore biosensor system; -7 K below M D(b) does not substantially bind to human CD28, CTLA-4 or ICOS; (c) increases T cell proliferation in a mixed lymphocyte reaction (MLR) assay; (d) increases interferon-γ production in an MLR assay; (e) increases IL-2 secretion in an MLR assay; (f) binds to human PD-1 and cynomolgus PD-1; (g) inhibits the binding of PD-L1 and / or PD-L2 to PD-1; (h) stimulates an antigen-specific memory response; (i) stimulates an antibody response; and (j) inhibits tumor cell proliferation in vivo. Anti-PD-1 antibodies that can be used in the present invention include monoclonal antibodies that specifically bind to human PD-1 and exhibit at least one, and in some embodiments, at least five, of the above properties. In some embodiments, the anti-PD-1 antibody is nivolumab. In some embodiments, the anti-PD-1 antibody is pembrolizumab.

[0154] In one embodiment, the anti-PD-1 antibody is nivolumab. (登録商標) "; formerly named 5C4, BMS-936558, MDX-1106 or ONO-4538) is a fully human IgG4 (S228P) PD-1 immune checkpoint inhibitor antibody that selectively inhibits interaction with PD-1 ligands (PD-L1 and PD-L2), thereby blocking downregulation of anti-tumor T cell function (U.S. Patent 8,008,449; Wang et al. In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates, Cancer Imm Res, 2(9):846-56 (2014)). In other embodiments, the anti-PD-1 antibody or fragment thereof cross-competes with nivolumab. In other embodiments, the anti-PD-1 antibody or fragment thereof binds to the same epitope as nivolumab. In certain embodiments, the anti-PD-1 antibody has the same CDRs as nivolumab.

[0155] In other embodiments, the anti-PD-1 antibody (or antigen-binding portion thereof) cross-competes with pembrolizumab. In certain embodiments, the anti-PD-1 antibody or fragment thereof binds to the same epitope as pembrolizumab. In certain embodiments, the anti-PD-1 antibody has the same CDRs as pembrolizumab. In other embodiments, the anti-PD-1 antibody is pembrolizumab. Pembrolizumab ("Keytruda") (登録商標) Pembrolizumab, also known as lambrolizumab and MK-3475, is a humanized monoclonal IgG4 antibody against the human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1). Pembrolizumab is described, e.g., in U.S. Patents 8,354,509 and 8,900,587; see also http: / / www.cancer.gov / drugdictionary?cdrid=69578 (last accessed: December 14, 2014). Pembrolizumab is approved by the FDA for the treatment of recurrent or refractory melanoma.

[0156] In other embodiments, the anti-PD-1 antibody (or antigen-binding portion thereof) cross-competes with MEDI0680. In yet other embodiments, the anti-PD-1 antibody or fragment thereof binds to the same epitope as MEDI0680. In certain embodiments, the anti-PD-1 antibody has the same CDRs as MEDI0680. In other embodiments, the anti-PD-1 antibody is MEDI0680 (formerly AMP-514), a monoclonal antibody. MEDI0680 is described, for example, in U.S. Patent 8,609,089 B2 or http: / / www.cancer.gov / drugdictionary?cdrid=756047 (last accessed: December 14, 2014).

[0157] In one embodiment, the first antibody is an anti-PD-1 antagonist. One example of an anti-PD-1 antagonist is AMP-224, a B7-DC Fc fusion protein. AMP-224 is described in US Publication 2013 / 0017199 or http: / / www.cancer.gov / publications / dictionaries / cancer-drug?cdrid=700595 (last accessed: July 8, 2015).

[0158] In other embodiments, the anti-PD-1 antibody (or antigen-binding portion thereof) cross-competes with BGB-A317. In certain embodiments, the anti-PD-1 antibody or fragment thereof binds to the same epitope as BGB-A317. In certain embodiments, the anti-PD-1 antibody has the same CDRs as BGB-A317. In certain embodiments, the anti-PD-1 antibody is BGB-A317, which is a humanized monoclonal antibody. BGB-A317 is described in U.S. Publication No. 2015 / 0079109.

[0159] In other embodiments, the anti-PD-1 antibody (or antigen-binding portion thereof) cross-competes with INCSHR1210 (SHR-1210). In certain embodiments, the anti-PD-1 antibody binds to the same epitope as INCSHR1210 (SHR-1210). In certain embodiments, the anti-PD-1 antibody has the same CDRs as INCSHR1210 (SHR-1210). In certain embodiments, the anti-PD-1 antibody is INCSHR1210 (SHR-1210), which is a human monoclonal antibody. INCSHR1210 (SHR-1210) is described in WO2015 / 085847.

[0160] In other embodiments, the anti-PD-1 antibody (or antigen-binding portion thereof) cross-competes with REGN-2810. In certain embodiments, the anti-PD-1 antibody binds to the same epitope as REGN-2810. In certain embodiments, the anti-PD-1 antibody has the same CDRs as REGN-2810. In certain embodiments, the anti-PD-1 antibody is REGN-2810, which is a human monoclonal antibody. REGN-2810 is described in WO2015 / 112800.

[0161] In other embodiments, the anti-PD-1 antibody (or antigen-binding portion thereof) cross-competes with PDR001. In certain embodiments, the anti-PD-1 antibody binds to the same epitope as PDR001. In certain embodiments, the anti-PD-1 antibody has the same CDRs as PDR001. In certain embodiments, the anti-PD-1 antibody is PDR001, which is a humanized monoclonal antibody. PDR001 is described in WO2015 / 112900.

[0162] In other embodiments, the anti-PD-1 antibody (or antigen-binding portion thereof) cross-competes with TSR-042 (ANB011). In certain embodiments, the anti-PD-1 antibody binds to the same epitope as TSR-042 (ANB011). In certain embodiments, the anti-PD-1 antibody has the same CDRs as TSR-042 (ANB011). In certain embodiments, the anti-PD-1 antibody is TSR-042 (ANB011), a humanized monoclonal antibody. TSR-042 (ANB011) is described in WO2014 / 179664.

[0163] In other embodiments, the anti-PD-1 antibody (or antigen-binding portion thereof) cross-competes with STI-1110. In certain embodiments, the anti-PD-1 antibody binds to the same epitope as STI-1110. In certain embodiments, the anti-PD-1 antibody has the same CDRs as STI-1110. In certain embodiments, the anti-PD-1 antibody is STI-1110, which is a human monoclonal antibody. STI-1110 is described in WO2014 / 194302.

[0164] Anti-PD-1 antibodies that can be used in the methods of the present invention also include isolated antibodies that specifically bind to human PD-1 and cross-compete with nivolumab for binding to human PD-1 (see, e.g., U.S. Patents 8,008,449 and 8,779,105; WO2013 / 173223). The ability of antibodies to cross-compete for binding to an antigen indicates that these antibodies bind to the same epitope region of the antigen and sterically hinder the binding of the other cross-competing antibody to that particular epitope region. These cross-competing antibodies are expected to have very similar functional properties to nivolumab by binding to the same epitope region of PD-1. Cross-competing antibodies can be easily identified based on their ability to cross-compete with nivolumab in standard PD-1 binding assays such as Biacore analysis, ELISA assays or flow cytometry (see, e.g., WO2013 / 173223).

[0165] In some embodiments, the antibody that cross-competes with nivolumab for binding to human PD-1 or binds to the same epitope region of human PD-1 is a monoclonal antibody.For administration to human subjects, these cross-competing antibodies are chimeric antibodies or humanized or human antibodies.Such chimeric, humanized or human monoclonal antibodies can be produced and isolated by methods well known in the art.

[0166] Anti-PD-1 antibodies that can be used in the methods of the invention also include antigen-binding portions of said antibodies. It is well established that the antigen-binding function of an antibody can be performed by fragments of a full-length antibody. Examples of binding fragments encompassed by the term "antigen-binding portion" of an antibody include: (i) V L , V H , C L and C H1 (ii) a F(ab')2 fragment, which is a bivalent fragment containing two Fab fragments linked by disulfide bridges in the hinge region; (iii) a V H and C H1 (iv) a single-arm V fragment of an antibody; Land V H It includes an Fv fragment consisting of domains or any combination thereof.

[0167] Anti-PD-1 antibodies suitable for use in the compositions of the invention are those that bind to PD-1 with high specificity and affinity, block binding of PD-L1 and / or PD-L2, and block the immunosuppressive effects of the PD-1 signaling pathway. In any of the compositions or methods described herein, an anti-PD-1 "antibody" includes an antigen-binding portion or fragment that binds to the PD-1 receptor and exhibits functional properties similar to whole antibodies with respect to ligand binding inhibition and immune system upregulation. In certain embodiments, the anti-PD-1 antibody or antigen-binding portion thereof cross-competes with nivolumab for binding to human PD-1. In other embodiments, the anti-PD-1 antibody or antigen-binding portion thereof is a chimeric, humanized, or human monoclonal antibody or portion thereof. In certain embodiments, the antibody is a humanized antibody. In other embodiments, the antibody is a human antibody. Antibodies of the IgG1, IgG2, IgG3, or IgG4 isotype may be used.

[0168] In certain embodiments, the anti-PD-1 antibody or antigen-binding portion thereof comprises a heavy chain constant region that is of a human IgG1 or IgG4 isotype. In certain other embodiments, the sequence of the IgG4 heavy chain constant region of the anti-PD-1 antibody or antigen-binding portion thereof comprises a S228P mutation, which replaces a serine residue in the hinge region with a proline residue normally found at the corresponding position in IgG1 isotype antibodies. This mutation, present in nivolumab, prevents Fab arm exchange with endogenous IgG4 antibodies while maintaining the low affinity for Fc receptor activation associated with wild-type IgG4 antibodies (Wang et al. (2014)). In yet other embodiments, the antibody comprises a light chain constant region that is a human kappa or lambda constant region. In other embodiments, the anti-PD-1 antibody or antigen-binding portion thereof is a monoclonal antibody or antigen-binding portion thereof. In certain embodiments of any of the methods of treatment described herein that include administration of an anti-PD-1 antibody, the anti-PD-1 antibody is nivolumab. In other embodiments, the anti-PD-1 antibody is pembrolizumab. In other embodiments, the anti-PD-1 antibody is selected from human antibodies 17D8, 2D3, 4H1, 4A11, 7D3, and 5F4, described in U.S. Patent 8,008,449. In yet other embodiments, the anti-PD-1 antibody is MEDI0680 (formerly AMP-514), AMP-224, or BGB-A31.

[0169] In certain embodiments of any of the methods of treatment described herein comprising administration of an anti-PD-1 antibody, the anti-PD-1 antibody is nivolumab. In other embodiments, the anti-PD-1 antibody is pembrolizumab. In other embodiments, the anti-PD-1 antibody is selected from human antibodies 17D8, 2D3, 4H1, 4A11, 7D3, and 5F4, described in U.S. Patent 8,008,449. In yet other embodiments, the anti-PD-1 antibody is MEDI0680 (formerly AMP-514) or AMP-224.

[0170] In some embodiments, the anti-PD-1 antibody used in the method may be replaced with other PD-1 or anti-PD-L1 antagonists. For example, anti-PD-L1 antibody may be replaced with anti-PD-1 antibody in the method disclosed herein, since anti-PD-L1 antibody blocks the interaction between PD-1 and PD-L1, thereby exerting a similar effect on the signal transduction pathway of PD-1. Thus, in some embodiments, the present invention relates to a method for treating a subject with a tumor derived from SCLC (e.g., recurrent SCLC), comprising administering to the subject a therapeutically effective amount of anti-PD-L1 antibody. In some embodiments, the anti-PD-L1 antibody is BMS-936559 (previously 12A4 or MDX-1105) (see, e.g., U.S. Patent 7,943,743; WO2013 / 173223). In other embodiments, the anti-PD-L1 antibody is MPDL3280A (also known as RG7446 and atezolizumab) (see, e.g., Herbst et al. (2013) J Clin Oncol 31(suppl):3000. Abstract; US Patent 8,217,149), MEDI4736 (also known as durvalumab; see Khleif (2013) In: Proceedings from the European Cancer Congress 2013; September 27-October 1, 2013; Amsterdam, The Netherlands. Abstract 802, US Patent 8,779,108, or US2014 / 0356353 filed May 6, 2014), or MSB0010718C (also known as avelumab; see US2014 / 0341917). In other embodiments, the anti-PD-L1 antibody is CX-072 (also known as CytomX; see WO2016 / 149201).

[0171] Combination therapy with anti-PD-1 or anti-PD-L1 antibodies In some embodiments, the anti-PD-1 antibody or anti-PD-L1 antibody is administered in combination with one or more other anti-cancer agents. In some embodiments, the one or more anti-cancer agents have been administered to the subject prior to administration of the anti-PD-1 or anti-PD-L1 antibody or prior to combination with the anti-PD-1 or anti-PD-L1 antibody. In some embodiments, the one or more anti-cancer agents have not been effective in treating the cancer. In some embodiments, the other anti-cancer agent is any anti-cancer agent described herein or known in the art. In some embodiments, the other anti-cancer agent is an anti-CTLA-4 antibody. In some embodiments, the other anti-cancer agent is a chemotherapeutic agent or a platinum-based doublet chemotherapeutic agent (PT-DC). In some embodiments, the other anti-cancer agent is an EGFR-targeted tyrosine kinase inhibitor (TKI). In some embodiments, the other anti-cancer agent is an anti-VEGF antibody. In other embodiments, the anti-cancer agent is a platinum agent (e.g., cisplatin, carboplatin), a mitotic inhibitor (e.g., paclitaxel, albumin-bound paclitaxel, docetaxel, taxotere, docecad), a fluorinated vinca alkaloid (e.g., vinflunine, javlor), vinorelbine, vinblastine, etoposide, or pemetrexed gemcitabine. In some embodiments, the other anti-cancer agent is 5-fluorouracil (5-FU). In some embodiments, the other anti-cancer agent is any other anti-cancer agent known in the art. In some embodiments, two or more additional anti-cancer agents are administered in combination with an anti-PD-1 or anti-PD-L1 antibody. In some embodiments, a PD-1 or PD-L1 antibody is combined with surgical resection and / or radiation therapy.

[0172] Anti-CTLA-4 antibody The anti-CTLA-4 antibodies of the invention bind to human CTLA-4 in a manner that disrupts the interaction of CTLA-4 with the human B7 receptor, which transduces a signal that leads to the inactivation of CTLA-4 receptor-bearing T cells, and thus disruption of the interaction effectively induces, enhances or prolongs the activation of such T cells, thereby inducing, enhancing or prolonging an immune response.

[0173] Human antibodies that specifically bind to CTLA-4 with high affinity are disclosed in U.S. Patents 6,984,720 and 7,605,238. Other anti-CTLA-4 monoclonal antibodies are described, for example, in U.S. Patents 5,977,318, 6,051,227, 6,682,736, and 7,034,121. The anti-CTLA-4 human antibodies disclosed in U.S. Patents 6,984,720 and 7,605,238 have been shown to exhibit one or more of the following properties: (a) a specific binding affinity of at least about 10 as determined by Biacore analysis; 7 M -1 or about 10 9 M -1 or about 10 10 M -1 ~10 11 M -1 or higher equilibrium binding constant (K a ), (b) specifically binds human CTLA-4 with a binding affinity reflected by at least about 10 3 , about 10 4 or about 10 5 m -1 s -1 The kinetic binding constant (k a );(c) at least about 10 3 , about 10 4 or about 10 5 m -1 s -1 The kinetic dissociation constant (k d and (d) inhibit the binding of CTLA-4 to B7-1 (CD80) and B7-2 (CD86). Anti-CTLA-4 antibodies useful in the present invention include monoclonal antibodies that specifically bind to human CTLA-4 and exhibit at least one, at least two, or in some embodiments, at least three of the above properties. An example of a clinical anti-CTLA-4 antibody is the human monoclonal antibody 10D1 (now known as ipilimumab and administered as Yervoy), disclosed in U.S. Patent 6,984,720. (登録商標) Ipilimumab is an anti-CTLA-4 antibody for use in the methods described herein. Another anti-CTLA-4 antibody useful in the methods is tremelimumab.

[0174] An example of a clinical anti-CTLA-4 antibody is the human monoclonal antibody 10D1 (now known as ipilimumab and Yervoy), disclosed in U.S. Patent 6,984,720. (登録商標) Ipilimumab is an anti-CTLA-4 antibody for use in the methods described herein. Ipilimumab is a fully human, IgG1 monoclonal antibody that blocks the binding of CTLA-4 to its B7 ligand, thereby stimulating T cell activation and improving overall survival (OS) in patients with advanced melanoma.

[0175] Another anti-CTLA-4 antibody useful for the present method is tremelimumab (also known as CP-675,206). Tremelimumab is a human IgG2 monoclonal anti-CTLA-4 antibody. Tremelimumab is described in WO / 2012 / 122444, U.S. Publication No. 2012 / 263677, or WO Publication No. 2007 / 113648A2.

[0176] Anti-CTLA-4 antibodies useful in the methods of the present invention also include isolated antibodies that specifically bind to human PD-1 and cross-compete with ipilimumab or tremelimumab for binding to human CTLA-4 or bind to the same epitope region of human CTLA-4 as ipilimumab or tremelimumab. In certain embodiments, the antibodies that cross-compete with ipilimumab or tremelimumab for binding to human CTLA-4 or bind to the same epitope region of PD-1 as ipilimumab or tremelimumab are antibodies that comprise a heavy chain of the human IgG1 isotype. For administration to human subjects, these cross-competing antibodies are chimeric, humanized or human antibodies. Useful anti-CTLA-4 antibodies also include antigen-binding portions of the above antibodies, such as Fab, F(ab'')2, Fd or Fv fragments.

[0177] Ipilimumab (Yervoy (登録商標)) is a fully human, IgG1 monoclonal antibody that blocks the binding of CTLA-4 to its B7 ligand, thereby stimulating T cell activation and improving overall survival (OS) in patients with advanced melanoma (Hodi et al. (2010) N Engl J Med 363:711-23). ​​Cotreatment with nivolumab and ipilimumab in a phase 1 trial produced rapid and profound tumor regression in a substantial proportion of patients with advanced melanoma and was significantly more effective than either antibody alone (Wolchok et al. (2013) N Engl J Med 369(2):122-33; WO2013 / 173223). However, to date it was not known whether this combination of immune-regulatory antibodies would be similarly effective in other tumor types.

[0178] Combination of anti-PD-1 and anti-CTLA-4 antibodies for the treatment of SCLC The present invention provides a combination therapy method for treating tumors originating from SCLC, in which an anti-PD-1 antibody is combined with another anti-cancer agent that is an antibody or antigen-binding portion thereof that specifically binds to CTLA-4 and inhibits CTLA-4 activity. It has been demonstrated herein that the combination of an anti-PD-1 antibody, nivolumab, and an anti-CTLA-4 antibody, ipilimumab, produces early and sustained anti-tumor activity in SCLC patients, particularly with certain dosing schedules (see Example 1). Thus, in one embodiment, the anti-CTLA-4 antibody used in combination with the anti-PD-1 antibody is ipilimumab. In one embodiment, the anti-CTLA-4 antibody is tremelimumab. In another embodiment, the anti-CTLA-4 antibody or antigen-binding portion thereof is an antibody or portion thereof that cross-competes with ipilimumab for binding to human CTLA-4. In one other embodiment, the anti-CTLA-4 antibody or antigen-binding portion thereof is a chimeric, humanized or human monoclonal antibody or portion thereof. In yet another embodiment, the anti-CTLA-4 antibody or antigen-binding portion thereof comprises a heavy chain constant region that is a human IgG1 or IgG4 isotype. In certain embodiments, the anti-CTLA-4 antibody comprises a heavy chain constant region that is a human IgG1 isotype.

[0179] Because immunotherapy through inhibition of immune checkpoints has previously demonstrated durability of clinical efficacy (see, e.g., WO2013 / 173223), the combination treatment, in alternative embodiments, may involve a finite number of administrations, e.g., about 1-10 administrations, or may involve administrations at longer intervals, e.g., about once every 3-6 months or about once every 1-2 years or longer.

[0180] In one embodiment of the method, the anti-PD-1 antibody is nivolumab. In another embodiment, it is pembrolizumab. In yet another embodiment, the anti-CTLA-4 antibody is ipilimumab. In a further embodiment, the anti-CTLA-4 antibody is tremelimumab. Generally, the anti-PD-1 and anti-CTLA-4 antibodies are formulated for intravenous administration. In one embodiment, when the anti-PD-1 and anti-CTLA-4 antibodies are administered in combination, they are administered within 30 minutes of each other. Either antibody may be administered first, i.e., in one embodiment, the anti-PD-1 antibody is administered before the anti-CTLA-4 antibody, while in another embodiment, the anti-CTLA-4 antibody is administered before the anti-PD-1 antibody. Generally, each antibody is administered by intravenous infusion over a period of 60 minutes. In certain embodiments, the anti-PD-1 and anti-CTLA-4 antibodies are administered simultaneously, either mixed as a single composition in a pharma- ceutically acceptable formulation for simultaneous administration, or simultaneously with each antibody in a separate composition in a pharma- ceutically acceptable formulation.

[0181] In one embodiment, the anti-PD-1 antibody is administered at a dose of 1 mg / kg once every three weeks, and the anti-CTLA-4 antibody is administered at a dose of 3 mg / kg once every three weeks. In another embodiment, the anti-PD-1 antibody at a dose of 1 mg / kg and the anti-CTLA-4 antibody at a dose of 3 mg / kg are administered once each, twice each, three times each, four times each, five times each, six times each, seven times each, eight times each, nine times each, or ten times each. In a further embodiment, the combination treatment of the anti-PD-1 antibody and the anti-CTLA-4 antibody is followed by a monotherapy of the anti-PD-1 antibody, for example, at a dose of 3 mg / kg, once every two weeks.

[0182] In certain embodiments, the anti-PD-1 antibody, or antigen-binding portion thereof, is administered at a subtherapeutic dose. In certain other embodiments, the anti-CTLA-4 antibody, or antigen-binding portion thereof, is administered at a subtherapeutic dose. In further embodiments, both the anti-PD-1 antibody, or antigen-binding portion thereof, and the anti-CTLA-4 antibody, or antigen-binding portion thereof, are each administered at a subtherapeutic dose.

[0183] Standard treatment for SCLC Standard treatment regimens for various types of cancer are well known to those skilled in the art. For example, the National Comprehensive Cancer Network (NCCN), an alliance of 21 major cancer centers in the United States, provides the NCCN Clinical Practice Guidelines in Oncology (NCCN GUIDELINES), which provide detailed, up-to-date information on standard treatment regimens for various cancers. (登録商標) ) has been published (NCCN GUIDELINES (登録商標) (2014), available at http: / / www.nccn.org / professionals / physician_gls / f_guidelines.asp, last accessed June 2, 2016).

[0184] Surgery, radiation therapy (RT) and chemotherapy are the three modalities commonly used in patients with SCLC. The most commonly used initial chemotherapy regimen is etoposide (TOPOSAR), also known as EP. (登録商標) Or Vepcid (登録商標) ) + Cisplatin (PLATINOL (登録商標) For people with extensive-stage small cell lung cancer, chemotherapy alone using the EP regimen is the standard treatment. However, other regimens that may be used are carboplatin (Paraplatin (登録商標) ) + Irinotecan (Camptosar (登録商標) ).

[0185] Although SCLC is highly sensitive to initial treatments including initial chemotherapy and / or radiation therapy, most patients ultimately die from SCLC recurrence. Therefore, there is a certain unmet need among patients with recurrent SCLC due to the lack of effective treatments after first-line therapy.

[0186] Pharmaceutical Compositions and Dosages The therapeutic agent of the present invention may be constituted as a composition, e.g., a pharmaceutical composition, comprising an antibody and a pharma- ceutically acceptable carrier. As used herein, a "pharma- ceutically acceptable carrier" includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, that are physiologically compatible. In some embodiments, the carrier for the antibody-containing composition is suitable for intravenous, intramuscular, subcutaneous, parenteral, spinal or epidermal administration (e.g., by injection or infusion). The pharmaceutical composition of the present invention may include one or more pharma- ceutical acceptable salts, antioxidants, aqueous and non-aqueous carriers, and / or adjuvants, such as preservatives, wetting agents, emulsifying agents, and dispersing agents.

[0187] Dosage regimens are adjusted to provide the optimal desired response, e.g., maximum therapeutic response and / or minimal adverse effects. For administration of anti-PD-1 antibodies, either as monotherapy or in combination with other anti-cancer agents (e.g., in combination with anti-CTLA-4 antibodies), dosages can range from about 0.01 to about 20 mg / kg, about 0.1 to about 10 mg / kg, about 0.1 to about 5 mg / kg, about 1 to about 5 mg / kg, about 2 to about 5 mg / kg, about 7.5 to about 12.5 mg / kg, or about 0.1 to about 30 mg / kg of patient body weight. For example, dosages can be about 0.1, about 0.3, about 1, about 2, about 3, about 5, or about 10 mg / kg body weight or about 0.35 mg / kg, about 15 mg / kg, about 25 mg / kg, about 35 mg / kg, or about 5 mg / kg body weight. Dosing schedules are generally based on the typical pharmacokinetic properties of the antibody, and examples of treatment regimes designed to achieve exposure resulting in sustained receptor occupancy (RO) involve administration about once a week, about once every two weeks, about once every three weeks, about once every four weeks, about once a month, about once every three to six months, or at longer intervals. In certain embodiments, such anti-PD-1 antibodies are administered to a subject about once every two weeks. In other embodiments, the antibody is administered about once every three weeks. Dosages and schedules may vary during the course of treatment. For example, dosing schedules for anti-PD-1 monotherapy may include administration of the antibody (i) about every two weeks for about six week cycles; (ii) about every three weeks for about six times, then about every three months; (iii) about every three weeks; (iv) about 3 mg / kg to about 10 mg / kg once, followed by about 1 mg / kg about every two to three weeks. Considering that IgG4 antibodies generally have a half-life of 2-3 weeks, dosage regimens for the anti-PD-1 antibodies of the invention include at least about 0.3 mg / kg to at least about 10 mg / kg body weight, at least about 1 mg / kg to at least about 5 mg / kg body weight, or at least about 1 mg / kg to at least about 3 mg / kg body weight by intravenous administration, with the antibody administered about every 14-21 days until complete response or disease progression is confirmed by about 6 weeks or in about 12 week cycles. In certain embodiments, anti-PD-1 monotherapy is administered at 3 mg / kg every 2 weeks until disease progression or unacceptable toxicity.In certain embodiments, the antibody treatment or any combination treatment disclosed herein is continued for at least about 1 month, at least about 3 months, at least about 6 months, at least about 9 months, at least about 1 year, at least about 18 months, at least about 24 months, at least about 3 years, at least about 5 years, or at least about 10 years.

[0188] When used in combination with other cancer drugs (e.g., in combination with anti-CTLA-4 antibodies), the dosage of anti-PD-1 antibodies may be reduced compared to monotherapy doses. A dosage of nivolumab typically lower than 3 mg / kg, but not below 0.001 mg / kg, is a subtherapeutic dosage. A subtherapeutic dosage of anti-PD-1 antibodies used in the methods herein is greater than 0.001 mg / kg and lower than 3 mg / kg. In certain embodiments, the subtherapeutic dosage is about 0.001 mg / kg to about 1 mg / kg, about 0.01 mg / kg to about 1 mg / kg, about 0.1 mg / kg to about 1 mg / kg, or about 0.001 mg / kg to about 0.1 mg / kg body weight. In certain embodiments, the subtherapeutic dose is at least about 0.001 mg / kg, at least about 0.005 mg / kg, at least about 0.01 mg / kg, at least about 0.05 mg / kg, at least about 0.1 mg / kg, at least about 0.5 mg / kg, or at least about 1.0 mg / kg body weight. Receptor occupancy data from 15 subjects receiving nivolumab at 0.3 mg / kg to 10 mg / kg indicates that PD-1 occupancy appears to be dose-independent in this dose range. Across all doses, the mean occupancy was 85% (range, 70% to 97%), and the mean plateau occupancy was 72% (range, 59% to 81%). In certain embodiments, a 0.3 mg / kg dose may allow sufficient exposure to reach maximum biological activity. Receptor occupancy data from 15 subjects receiving nivolumab at 0.3 mg / kg to 10 mg / kg indicates that PD-1 occupancy appears to be dose-independent in this dose range. Across all doses, the mean occupancy was 85% (range, 70%-97%) and the mean plateau occupancy was 72% (range, 59%-81%) (Brahmer et al. (2010) J Clin Oncol 28:3167-75). Therefore, the 0.3 mg / kg dose may allow sufficient exposure to lead to maximal bioactivity.

[0189] Although high nivolumab monotherapy doses up to 10 mg / kg every 2 weeks have been achieved without reaching the maximum tolerated dose (MTD), substantial toxicity has been reported in other trials of checkpoint inhibitors and antiangiogenic therapy (see, e.g., Johnson et al. (2013) Cancer Immunol Res 1:373-77; Rini et al. (2011) Cancer 117:758-67), supporting the selection of a nivolumab dose lower than 10 mg / kg.

[0190] In one embodiment, the dose of the anti-PD-1 antibody (or anti-PD-L1 antibody) is a fixed dose in the pharmaceutical composition. In other embodiments, the methods of the present invention can be used with a flat dose (a dose given to a patient regardless of the patient's weight). For example, a flat dose of nivolumab can be about 240 mg. For example, a flat dose of pembrolizumab can be about 200 mg. In one embodiment, the anti-PD-1 antibody or antigen-binding portion thereof is administered at a dose of about 240 mg. In one embodiment, the anti-PD-1 antibody or antigen-binding portion thereof is administered at a dose of about 360 mg. In one embodiment, the anti-PD-1 antibody or antigen-binding portion thereof is administered at a dose of about 480 mg. In one embodiment, 360 mg of the anti-PD-1 antibody or antigen-binding fragment is administered to the subject once every three weeks. In another embodiment, 480 mg of the anti-PD-1 antibody or antigen-binding fragment is administered to the subject once every four weeks.

[0191] Ipilimumab (Yervoy (登録商標)) is approved for the treatment of melanoma at 3 mg / kg intravenously every 3 weeks for 4 doses. Thus, in certain embodiments, about 3 mg / kg is the maximum dose of ipilimumab used in combination with an anti-PD-1 antibody, but in certain embodiments, an anti-CTLA-4 antibody such as ipilimumab, when combined with nivolumab, may be administered about every 2 weeks or every 3 weeks at a dose in the range of about 0.3 to about 10 mg / kg, about 0.5 to about 10 mg / kg, about 0.5 to about 5 mg / kg, or about 1 to about 5 mg / kg body weight. In other embodiments, ipilimumab is administered on a different dosing schedule than nivolumab. In some embodiments, ipilimumab is administered about every week, about every 2 weeks, about every 3 weeks, about every 4 weeks, about every 5 weeks, about every 6 weeks, about every 7 weeks, about every 8 weeks, about every 9 weeks, about every 10 weeks, about every 11 weeks, about every 12 weeks, or about every 15 weeks. A dose of ipilimumab that is typically lower than 3 mg / kg every 3 weeks, but not less than 0.001 mg / kg, is a subtherapeutic dose. A subtherapeutic dose of an anti-CTLA-4 antibody used in the methods herein is greater than 0.001 mg / kg and lower than 3 mg / kg. In some embodiments, a subtherapeutic dose is about 0.001 mg / kg to about 1 mg / kg, about 0.01 mg / kg to about 1 mg / kg, about 0.1 mg / kg to about 1 mg / kg, or about 0.001 mg / kg to about 0.1 mg / kg body weight. In some embodiments, the subtherapeutic dose is at least about 0.001mg / kg, at least about 0.005mg / kg, at least about 0.01mg / kg, at least about 0.05mg / kg, at least about 0.1mg / kg, at least about 0.5mg / kg or at least about 1.0mg / kg body weight.It has been shown that 3mg / kg nivolumab and 3mg / kg ipilimumab combination administration exceeds the MTD in melanoma population, while 1mg / kg nivolumab + 3mg / kg ipilimumab or 3mg / kg nivolumab + 1mg / kg ipilimumab combination is found to be tolerable in melanoma patients (Wolchok et al., N Engl J Med 369(2):122-33(2013)).Thus, nivolumab is tolerated at up to 10 mg / kg intravenous administration every two weeks, although in some embodiments, the dose of the anti-PD-1 antibody does not exceed about 3 mg / kg when combined with ipilimumab. In some embodiments, based on the risk-benefit and PK-PD assessment, the dosages used include combinations of about 1 mg / kg nivolumab + about 3 mg / kg ipilimumab, about 3 mg / kg nivolumab + about 1 mg / kg ipilimumab, or about 3 mg / kg nivolumab + about 3 mg / kg ipilimumab, each administered at a dosing frequency of about once every 2-4 weeks, in some embodiments, about once every 2 weeks or about once every 3 weeks. In certain other embodiments, nivolumab is administered at a dosage of about 0.1 mg / kg, about 0.3 mg / kg, about 1 mg / kg, about 2 mg / kg, about 3 mg / kg or about 5 mg / kg in combination with ipilimumab administered at a dosage of about 0.1 mg / kg, about 0.3 mg / kg, about 1 mg / kg, about 2 mg / kg, about 3 mg / kg or about 5 mg / kg, about once every two weeks, about once every three weeks or about once every four weeks.

[0192] In some embodiments, the combination of anti-PD-1 antibody and anti-CTLA-4 antibody is administered intravenously to the subject in the induction phase once, twice, three times or four times, about once every two or three weeks. In some embodiments, the combination of nivolumab and ipilimumab is administered intravenously about every two or three weeks about four times during the induction phase. The induction phase is followed by a maintenance phase during which the anti-PD-1 antibody alone is administered to the subject at a dose of about 0.1 mg / kg, about 0.3 mg / kg, about 1 mg / kg, about 2 mg / kg, about 3 mg / kg, about 5 mg / kg or about 10 mg / kg about every two or three weeks, as long as the treatment is effective or until unmanageable toxicity or disease progression occurs. In some embodiments, nivolumab is administered at a dose of about 3 mg / kg body weight about every two weeks during the maintenance phase.

[0193] The antibodies disclosed herein may be administered according to a "treatment cycle" or "cycle" (these terms are used interchangeably herein). As used herein, the term "cycle" refers to a course of treatment that is repeated at regular intervals with a rest period in between. For example, one week of treatment followed by three weeks of rest is one treatment cycle. In certain embodiments, the anti-PD-1 antibody and / or anti-CTLA-4 antibody are administered for at least 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 cycles. In certain embodiments, the administration of the anti-PD-1 antibody and anti-CTLA-4 antibody is repeated four times (4 cycles).

[0194] In some embodiments, the anti-PD-1 antibody and the anti-CTLA-4 antibody are formulated as a single composition, wherein the dose of the anti-PD-1 antibody and the dose of the CTLA-4 antibody are combined in a ratio of 1:50, 1:40, 1:30, 1:20, 1:10, 1:5, 1:3, 1:1, 3:1, 5:1, 10:1, 20:1, 30:1, 40:1, or 50:1. In other embodiments, the dose of the CTLA-4 antibody is a fixed dose. In some embodiments, the dose of the CTLA-4 antibody is a flat dose given to the patient regardless of body weight. In a specific embodiment, the flat dose of the anti-CTLA-4 antibody is about 80 mg.

[0195] For the combination of nivolumab with other anti-cancer drugs, these drugs are administered at their approved doses. Treatment continues as long as clinical benefit is observed or until unacceptable toxicity or disease progression occurs. Nevertheless, in some embodiments, the doses of these anti-cancer drugs administered are significantly lower than the approved doses, i.e., subtherapeutic doses of the drugs are administered in combination with the anti-PD-1 antibody. The anti-PD-1 antibody can be administered at a dose that has been shown in clinical trials to produce the highest efficacy as a monotherapy, for example, about 3 mg / kg of nivolumab administered about once every 3 weeks (Topalian et al., N Engl J Med 366:2443-54 (2012a); Topalian et al., Curr Opin Immunol 24:207-12 (2012b)), or at a significantly lower dose, i.e., subtherapeutic dose. In some embodiments, the anti-PD-1 antibody is administered at about 3 mg / kg, about once every 3 weeks.

[0196] Dosage and frequency vary according to the half-life of the antibody in the subject. Generally, human antibodies show the longest half-life, followed by humanized antibodies, chimeric antibodies and non-human antibodies. Dosage and frequency can vary according to whether the treatment is preventive or therapeutic. In preventive applications, relatively low doses are generally administered less frequently and for a long period of time. Some patients continue to receive treatment for life. In therapeutic applications, relatively high doses at relatively short intervals may be required until disease progression is reduced or stopped and until the patient shows partial or complete improvement of disease symptoms. The patient can then be administered a preventive regime.

[0197] The actual dosage level of one or more active ingredients in the pharmaceutical composition of the present invention may vary in order to obtain an amount of active ingredient that is effective to achieve the desired therapeutic effect for a particular patient, composition and mode of administration without excessive toxicity to the patient.The selected dosage depends on a variety of pharmacokinetic factors, including the activity of the particular composition of the present invention used, the route of administration, the time of administration, the excretion rate of the particular compound used, the duration of treatment, other drugs, compounds and / or substances used in combination with the particular composition used, the age, sex, weight, condition, general health and previous history of the patient being treated, and similar factors well known in the medical field.The composition of the present invention may be administered by one or more routes of administration using one or more of a variety of methods well known in the art.As is well known to those skilled in the art, the route and / or mode of administration will vary depending on the desired result.

[0198] In certain embodiments, a subject being treated with a combination of an anti-PD-1 antibody and an anti-CTLA-4 antibody can be further treated with an anti-PD-1 antibody monotherapy.

[0199] Because anti-PD-1 and anti-PD-L1 target the same signaling pathway and have shown comparable levels of similarity in clinical trials in a variety of cancers, including renal cell carcinoma (see Brahmer et al. (2012) N Engl J Med 366:2455-65; Topalian et al. (2012a) N Engl J Med 366:2443-54; WO2013 / 173223), an anti-PD-L1 antibody may be substituted for an anti-PD-1 antibody in any of the therapeutic methods described herein. In one embodiment, the anti-PD-L1 antibody is BMS-936559 (formerly 12A4 or MDX-1105) (see, e.g., U.S. Patent 7,943,743; WO2013 / 173223). In other embodiments, the anti-PD-L1 antibody is MPDL3280A (also known as RG7446 and atezolizumab) (see, e.g., Herbst et al. (2013) J Clin Oncol 31(suppl):3000. Abstract; US Patent 8,217,149) or MEDI4736 (Khleif (2013) In: Proceedings from the European Cancer Congress 2013; September 27-October 1, 2013; Amsterdam, The Netherlands. Abstract 802). In certain embodiments, the antibodies that cross-compete with the above PD-L1 antibodies for binding to human PD-L1 or bind to the same epitope on human PD-L1 are monoclonal antibodies. For administration to human subjects, these cross-competing antibodies can be chimeric, humanized or human antibodies. Such chimeric, humanized or human monoclonal antibodies can be produced and isolated by methods well known in the art.

[0200] kit Also within the scope of the present invention are kits comprising anti-PD-1 antibodies and other anti-cancer agents for therapeutic use. The kits generally include a label indicating the intended use and instructions for use of the contents of the kit. The term label includes any writing or recording medium on or with the kit or that otherwise accompanies the kit. Thus, the present invention provides a kit for treating a subject having a tumor derived from SCLC, the kit comprising: (a) a PD-1 antibody or antigen-binding portion thereof in an amount of about 4 mg to about 500 mg; and (b) instructions for using the PD-1 antibody or antigen-binding portion thereof in any of the methods disclosed herein. The present invention further provides a kit for treating a subject having a tumor derived from SCLC, the kit comprising: (a) a PD-1 antibody or antigen-binding portion thereof in an amount of about 4 mg to about 500 mg; (b) a CTLA-4 antibody or antigen-binding portion thereof in an amount of about 4 mg to about 500 mg; and (c) instructions for using the PD-1 antibody or antigen-binding portion thereof and the CTLA-4 antibody or antigen-binding portion thereof in any of the methods disclosed herein. In some embodiments, the kit comprises a PD-1 antibody or antigen-binding portion thereof and a CTLA-4 antibody or antigen-binding portion thereof as separate compositions. In some embodiments, the kit comprises a PD-1 antibody or antigen-binding portion thereof and a CTLA-4 antibody or antigen-binding portion thereof as a single composition. In some embodiments, the anti-PD-1 and anti-CTLA-4 antibodies can be co-packaged in a unit dosage form. In some embodiments for human patient treatment, the kit comprises an anti-human PD-1 antibody disclosed herein, such as nivolumab or pembrolizumab. In other embodiments, the kit comprises an anti-human CTLA-4 antibody disclosed herein, such as ipilimumab or tremelimumab.

[0201] The present invention is further illustrated by the following examples, which should not be construed as further limiting. The contents of all references cited throughout this specification are expressly incorporated herein by reference. EXAMPLES

[0202] Example 1 Small cell lung cancer (SCLC), which accounts for approximately 14% of all lung cancers, is strongly correlated with smoking, has no known oncogenic drivers, and has a high mutation rate. Most patients present with extensive disease, characterized by widespread metastases and poor survival. Although 35%-86% of patients respond to first-line chemotherapeutic agents, the disease progresses rapidly and outcomes with second-line treatments are poor.

[0203] The standard first-line chemotherapy agent for SCLC is the platinum-etoposide doublet, with topotecan as second-line treatment in the United States (US) and European Union (EU) and amrubicin as second-line treatment in Japan. Response rates to topotecan are 23% and 9% in platinum-sensitive and platinum-resistant / refractory patients, respectively, but are not durable.

[0204] Nivolumab, a fully human IgG4 programmed death 1 (PD-1) immune checkpoint inhibitor antibody, significantly improved overall survival compared with docetaxel in two phase 3 trials in patients with non-SCLC (NSCLC) that had progressed after first-line platinum-based doublet chemotherapy agents, with a favorable safety profile, leading to approval in the United States for the treatment of patients with metastatic NSCLC and in the EU for the treatment of patients with locally advanced or metastatic squamous NSCLC. Ipilimumab, a fully human IgG1 cytotoxic T-lymphocyte antigen 4 (CTLA-4) immune checkpoint inhibitor, significantly improved overall survival in two phase 3 trials in patients with advanced melanoma, leading to approval for this indication in the United States and the EU.

[0205] Preclinical data have shown that the combination of PD-1 and CTLA-4 receptor blockade improves antitumor activity, and the combination of nivolumab and ipilimumab has shown deep and durable responses in several tumor types. The combination of nivolumab and ipilimumab has been approved in the United States for the treatment of advanced melanoma. Based on the efficacy of the combination treatment in melanoma, clinical trials as phase 1 / 2 trials to test the activity and safety of nivolumab as monotherapy or in combination with ipilimumab have been designed in several advanced or metastatic tumor types. Evaluation of nivolumab monotherapy and the combination of nivolumab and ipilimumab in patients with advanced or metastatic solid tumors, for which no standard of care exists in advanced lines of treatment, may provide evidence of antitumor activity as a basis for further clinical development in these tumor types. Here, we report the activity, safety, and biomarker analysis for the SCLC cohort.

[0206] method Clinical trial design and participants This was an international, phase 1 / 2, two-stage, open-label, multi-arm trial. Patients with SCLC were enrolled at 23 sites in 6 countries (Finland, Germany, Italy, Spain, the UK, and the USA). Eligible patients had histologically or cytologically confirmed limited-stage or extensive-stage SCLC and disease progression after at least one platinum-based chemotherapy regimen. Patients with platinum-sensitive or platinum-resistant disease (relapse ≥90 days or <90 days after or during chemotherapy, respectively) were eligible regardless of programmed death-ligand 1 (PD-L1) expression. Patients were ≥18 years old, had an Eastern Cooperative Oncology Group (ECOG) activity index of 0 or 1 (on a 0-5 scale: 0, no symptoms; 1, mild symptoms; higher numbers indicate greater tumor-related disability), and adequate organ function. Patients were required to have a baseline tumor biopsy or archived tumor material for measurable disease and biomarker analysis by Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1. Tumor material was acceptable as were biopsies performed before the screening period, provided that the biopsy was performed up to 3 months before treatment initiation and no other systemic cancer treatments had been administered during that time. Baseline laboratory tests required for eligibility assessment included white blood cell count, neutrophils, platelets, hemoglobin, serum creatinine, alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin, albumin, lipase and amylase. Important exclusion criteria included active brain or leptomeningeal metastases, history of autoimmune disease (other than leukoplakia, type I diabetes, residual hypothyroidism for autoimmune thyroiditis requiring hormone replacement therapy only or conditions not predicted to recur in the absence of external triggers), need for systemic corticosteroids in immunosuppressive doses (>10 mg / day prednisone equivalent) for 2 weeks prior to study drug administration, and prior treatment with antibodies modulating T cell function or checkpoint pathways. Patients were also excluded if they had a positive hepatitis B virus or human immunodeficiency virus test or if they had unresolved toxicity from prior anticancer treatment.

[0207] Patient selection was not based on survival estimates: median survival for patients with recurrent SCLC has been reported to range from approximately 3.5 to 12 months.

[0208] The study protocol was approved by the Institutional Review Board or Ethics Committee of each participating institution. The study was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice as defined by the International Conference on Harmonization. Written informed consent was obtained from all patients before any study-specific procedures were performed.

[0209] method Dosing considerations in the combination cohort were as follows: 1 mg / kg nivolumab + 3 mg / kg ipilimumab regimen is the approved dose for advanced melanoma treatment; 3 mg / kg nivolumab + 1 mg / kg ipilimumab regimen was selected to maximize nivolumab dose based on nivolumab exposure-response data (1 mg / kg vs. 3 mg / kg); and an initial dose-escalation safety evaluation phase was performed (starting with 1 mg / kg nivolumab + 1 mg / kg ipilimumab) to ensure that nivolumab + ipilimumab was tolerable in patients with SCLC. The safety of the 1 mg / kg nivolumab + 3 mg / kg ipilimumab and 3 mg / kg nivolumab + 1 mg / kg ipilimumab regimens has been previously evaluated in studies in other tumor types.

[0210] Patients with SCLC were assigned to one of the following treatment cohorts: nivolumab as monotherapy at 3 mg / kg body weight administered intravenously every 2 weeks (nivolumab-3) or combination treatment of nivolumab + ipilimumab administered intravenously every 3 weeks for 4 cycles at dose level 1 (nivolumab 1 mg / kg + ipilimumab 1 mg / kg [nivolumab-1 / ipilimumab-1]), dose level 2 (nivolumab 1 mg / kg + ipilimumab 3 mg / kg [nivolumab-1 / ipilimumab-3]) or dose level 2b (nivolumab 3 mg / kg + ipilimumab 1 mg / kg [nivolumab-3 / ipilimumab-1]), followed by nivolumab at 3 mg / kg every 2 weeks. See Figure 1. An initial dose escalation safety evaluation of the combination arm was performed to ensure that the planned combination regimen was tolerable in patients with SCLC. The first dose cohort was level 1. If this was deemed acceptable, level 2 was initiated. If dose level 2 was deemed unacceptable, dose level 2b was investigated. The combination arm continued enrolling patients once the highest dose level for further investigation was identified in the dose escalation safety evaluation phase. Patients on active treatment were required to follow up for at least 6 weeks after initiation of study treatment before the tolerability of the dose level was determined based on predefined tolerability assessment criteria. However, tolerability beyond 6 weeks was also considered. For combination treatment, nivolumab was administered first (60 min infusion) followed by ipilimumab (90 min infusion) in accordance with previous trials evaluating nivolumab + ipilimumab. Patients received open-label treatment until disease progression or the occurrence of unacceptable toxicity (Figure 1). Treatment beyond RECIST, version 1.1-defined progression was permitted if the patient tolerated and benefited from the treatment based on investigator assessment. Using an interactive voice response system, patients were enrolled in one of four cohorts in a sequential fashion or assigned if more than one cohort was open for enrollment. Patients who progressed on nivolumab-3 could cross over to the combination cohort.

[0211] No dose reductions or modifications were permitted for nivolumab or ipilimumab. Criteria for dose delays (which were necessary for protocol-defined reasons) and treatment discontinuations are detailed separately.

[0212] Radiographic tumor assessments were performed at baseline, every 6 weeks for the first 24 weeks, and then every 12 weeks until disease progression (investigator assessment according to RECIST, version 1.1-defined progression) or treatment discontinuation. Survival was monitored continuously while patients were on treatment and every 3 months after treatment discontinuation. Safety was evaluated throughout the study (Table 1), and adverse events were staged according to the National Cancer Institute's Common Terminology Criteria for Adverse Events, version 4.0. [Table 1] *Liver function tests, blood urea nitrogen or serum urea level, creatinine, albumin, calcium, magnesium, sodium, potassium, chloride, lactate dehydrogenase, glucose, amylase, lipase and complete blood differential test for thyroid stimulating hormone. WOCBP=Women of childbearing potential. X=Evaluation to be performed.

[0213] Tumor PD-L1 protein expression was retrospectively assessed in pretreatment (archived or fresh) tumor biopsy specimens using a validated, automated immunohistochemical assay (Dako North America, Carpinteria, CA, USA) that uses a rabbit anti-human PD-L1 antibody (clone 28-8, Epitomics Inc, Burlingame, CA, USA). Tumor PD-L1 expression was classified as positive when tumor cell membrane staining (at any intensity) was observed in tumor cells with a predefined expression level of ≥1% or ≥5% in sections that contained ≥100 evaluable tumor cells. In the initial study protocol, analysis of specimens was not required prior to patient randomization; the protocol was later amended, and this was required by a study amendment (for all cohorts in the study).

[0214] result The primary endpoint of this trial was the proportion of patients with a confirmed objective response (defined as the number of patients with a best overall response of complete or partial response [according to investigator-assessed RECIST, version 1.1 criteria] divided by the number of patients assigned to the trial). The objective response rate was the primary endpoint because the goal of this trial was to evaluate the antitumor activity of nivolumab monotherapy or in combination with ipilimumab.

[0215] Secondary endpoints included overall survival, progression-free survival, duration of response, and rate of treatment-related adverse events leading to treatment discontinuation. Overall survival was defined as the time from the date of treatment assignment to the date of death from any cause. Progression-free survival was defined as the time from the date of treatment assignment to the date of first reported tumor progression as determined by the investigator (per RECIST, version 1.1) or death from any cause, whichever occurred first. Duration of response was defined as the time from best overall response, partial or complete response, to the date of reported disease progression (using RECIST, version 1.1) or death from any cause. Correlation of PD-L1 expression by tumor cells with antitumor activity was a prespecified exploratory endpoint.

[0216] All activity analyses were performed based on original treatment assignment, not by crossover condition.

[0217] statistical analysis In parallel with the safety evaluation phase of the combination arm (as described in Methods), patient enrollment followed the Simon two-stage design (see Simon R., Control Clin. Trials 10:1-10 (1989)). This design was used to test whether nivolumab and / or the combination of nivolumab and ipilimumab produced clinically interesting objective response rates in each of the tumor types; it also limits the expected number of patients receiving treatment when the true response rate is not of clinical value. The two-stage trial was performed independently in each cohort.

[0218] For each cohort, Simon's design requires 18 treated patients in the first stage, and ends the cohort at stage 1 if there is not 1 or more responders among the 18 treated patients in the cohort. Otherwise, 2 or more responders are identified in a maximum of 18 patients in the cohort, and additional patients are assigned in that cohort, up to a total of 40 treated patients. At the end of the second stage, if there are 8 or more responders among the 40 treated patients in any single cohort, the treatment is deemed clinically significant.

[0219] Only treatment arms that met the objective response rate threshold progressed from Phase 1 to Phase 2. Enrollment in Phase 2 in a treatment arm continued even if the other treatment arm was still in Phase 1.

[0220] For phase 2, after completion of enrollment of the initial 40 patients, up to 100 additional patients were assigned to the nivolumab monotherapy and combination arms in each treatment arm (including those assigned in phase 1). Once nivolumab monotherapy or nivolumab-1 / ipilimumab-3 progressed to phase 2, evaluation of dose level 2b (nivolumab-3 / ipilimumab-1) in phase 2 began.

[0221] All analyses included treated patients who enrolled at least 90 days before database closure. Overall activity analyses were performed based on original treatment assignment, not by crossover condition.

[0222] Objective response rates were summarized by binomial response rates using the Clopper-Pearson method and corresponding two-sided 95% exact confidence intervals (CIs). Progression-free survival and overall survival were summarized descriptively using the Kaplan-Meier method; medians were calculated with two-sided 95% CIs calculated using the Brookmeyer Crowley method. Only treatment cohorts with more than six patients are represented in the Kaplan-Meier plots. Patients with less than 12 weeks of follow-up were excluded from the Kaplan-Meier plots. Progression-free survival and overall survival were estimated with two-sided 95% CIs calculated using the Greenwood formula. Duration of response was summarized using the Kaplan-Meier product limit method. For PD-L1 biomarker analysis, best overall response was summarized for each cohort by baseline PD-L1 expression and objective response rate, and exact 95% CIs were calculated using the Clopper-Pearson method. All statistical analyses were performed using SAS software (version 9.02).

[0223] result We enrolled and treated 216 patients with SCLC: 98 in the nivolumab 3 mg / kg cohort, 3 in the nivolumab 1 mg / kg + ipilimumab 1 mg / kg cohort, 61 in the nivolumab 1 mg / kg + ipilimumab 3 mg / kg cohort, and 54 in the nivolumab 3 mg / kg + ipilimumab 1 mg / kg cohort (Figure 1). Three patients in the nivolumab 3 mg / kg group, two in the nivolumab 1 mg / kg + ipilimumab 3 mg / kg group, and four in the nivolumab 3 mg / kg + ipilimumab 1 mg / kg group had not received first-line platinum therapy and did not meet the eligibility criteria but were treated. Of the three patients in the nivolumab 1 mg / kg + ipilimumab 1 mg / kg cohort, none discontinued treatment due to treatment-related adverse events within the first 6 weeks, allowing enrollment into the other two combination cohorts, nivolumab 1 mg / kg + ipilimumab 3 mg / kg and nivolumab 3 mg / kg + ipilimumab 1 mg / kg. At the time of database closure, all patients had at least 12 weeks of follow-up, and the median follow-up for patients on the trial (including those who died or discontinued treatment) was 198.5 days (IQR 163.0-464.0) in the nivolumab 3 mg / kg cohort, 302 days (IQR not calculable) in the nivolumab 1 mg / kg + ipilimumab 1 mg / kg cohort, 361.0 days (273.0-470.0) in the nivolumab 1 mg / kg + ipilimumab 3 mg / kg cohort, and 260.5 days (248.0-288.0) in the nivolumab 3 mg / kg + ipilimumab 1 mg / kg cohort (Table 2). Median follow-up for overall survival data is shown in the Appendix (Table 2). Baseline characteristics are shown in Table 3; roughly half of the patients had been treated with two or more prior regimens and approximately one-third had platinum-resistant disease. [Table 2] Data are presented as n, n (%) or median (IQR) unless otherwise indicated. All patients were enrolled at least 90 days before database closure. AE = adverse event. IQR = interquartile range. NA = not applicable. *Patients remaining on study at database lock on November 6, 2015. **Patients remaining on study at database lock on March 24, 2016 (n=98, nivolumab-3; n=61, nivolumab-1 / ipilimumab-3; n=55, nivolumab-3 / ipilimumab-1). †One patient with disease progression and one patient who requested treatment discontinuation had treatment-related adverse events related to treatment discontinuation in the nivolumab-3 cohort. ‡Includes patients still on treatment and non-treated patients with ongoing follow-up. [Table 3] Data are expressed as n (%) or median (IQR) unless otherwise indicated. *Three patients in the nivolumab 3 mg / kg group, two in the nivolumab 1 mg / kg + ipilimumab 3 mg / kg group, and four in the nivolumab 3 mg / kg + ipilimumab 1 mg / kg group did not receive first-line platinum therapy and did not meet the eligibility criteria but were treated and included in the analysis. †Patients who relapsed <90 days after chemotherapy were included. ‡Percentage of PD-L1-evaluable patients; may exceed 100% due to rounding.

[0224] Patients received a median of 3 to 5 infusions of nivolumab (IQR 2.0 to 6.0) in the nivolumab 3 mg / kg cohort, 9.0 infusions of nivolumab (IQR not calculable) and 4.0 infusions of ipilimumab (IQR not calculable) in the nivolumab 1 mg / kg + ipilimumab 1 mg / kg cohort, 3.0 infusions each of nivolumab (2.0 to 14.0) and ipilimumab (2.0 to 4.0) in the nivolumab 1 mg / kg + ipilimumab 3 mg / kg cohort, and 2.0 infusions each of nivolumab (2.0 to 6.0) and ipilimumab (2.0 to 4.0) in the nivolumab 3 mg / kg + ipilimumab 1 mg / kg cohort. At the time of analysis, 77 (79%) patients had discontinued nivolumab 3 mg / kg, 42 (69%) patients had discontinued nivolumab 1 mg / kg + ipilimumab 3 mg / kg, and 43 (80%) patients had discontinued nivolumab 3 mg / kg + ipilimumab 1 mg / kg; the most common reason was disease progression (Figure 1; Table 4). Two patients had discontinued nivolumab 1 mg / kg + ipilimumab 1 mg / kg (one due to disease progression and one due to an adverse event unrelated to study drug). [Table 4] Data are presented as n, n (%) or median (IQR) unless otherwise indicated. All patients were enrolled at least 90 days before database closure. AE = adverse event. IQR = interquartile range NA = not applicable. *Patients remaining on study at database closure on November 6, 2015. **Patients remaining on study at database lock on March 24, 2016 (n=98, nivolumab-3; n=61, nivolumab-1 / ipilimumab-3; n=55, nivolumab-3 / ipilimumab-1). †One patient with disease progression and one patient who requested treatment discontinuation had treatment-related adverse events related to treatment discontinuation in the nivolumab-3 cohort. ‡Includes patients still on treatment and non-treated patients with ongoing follow-up.

[0225] By blinded central review, 10 of 98 patients (10% [95% CI 5-18]) received nivolumab 3 mg / kg, 14 of 61 patients (23% [13-36]) received nivolumab 1 mg / kg plus ipilimumab 3 mg / kg, and 10 of 54 patients (19% [9-31]) received nivolumab 3 mg / kg plus ipilimumab 1 mg / kg achieved a confirmed objective response (Table 5; Figures 3A-3C). One of three patients (33%) who received nivolumab 1 mg / kg plus ipilimumab 1 mg / kg achieved an objective response (complete response; data not shown). Two or more of 18 patients in a particular arm met the predefined threshold that the arm must have a confirmed partial or complete response before continuing enrollment for stage 2. In the nivolumab 3 mg / kg cohort, 7 patients died before disease evaluation, 4 patients discontinued early (1 due to toxicity, 3 due to clinical progression), and 1 patient withdrew consent before completing the protocol; in the nivolumab 1 mg / kg + ipilimumab 3 mg / kg cohort, 5 patients died before disease evaluation, 1 patient discontinued early due to clinical progression, 1 patient was not evaluated because the first evaluation was not performed, and 1 patient withdrew consent for scan and follow-up visits; and in the nivolumab 3 mg / kg + ipilimumab 1 mg / kg cohort, 2 patients died before disease evaluation, 3 patients discontinued early (2 due to clinical progression and 1 due to toxicity), and CT scan was not performed in 1 patient. The median response duration was not reached with nivolumab 3 mg / kg (95% CI 4.4 to not reached), 7.7 months with nivolumab 1 mg / kg plus ipilimumab 3 mg / kg (4.0 to not reached), and 4.4 months with nivolumab 3 mg / kg plus ipilimumab 1 mg / kg (3.7 to not reached). Sixteen patients had a response duration longer than 6 months: six patients in the nivolumab 3 mg / kg group, one patient in the nivolumab 1 mg / kg plus ipilimumab 1 mg / kg group, eight patients in the nivolumab 1 mg / kg plus ipilimumab 3 mg / kg group, and one patient in the nivolumab 3 mg / kg plus ipilimumab 1 mg / kg group (median 9.6 months [IQR 7.1 to 14.3]). The median times to response are shown in Table 5.At the time of database closure, 8 of 10 responses (80%) in the nivolumab 3 mg / kg group, 1 of 3 responses in the nivolumab 1 mg / kg + ipilimumab 1 mg / kg group, 7 of 14 responses (50%) in the nivolumab 1 mg / kg + ipilimumab 3 mg / kg group, and 7 of 10 responses (70%) in the nivolumab 3 mg / kg + ipilimumab 1 mg / kg group were ongoing. Thirty patients in the nivolumab 3 mg / kg cohort, 15 patients in the nivolumab 1 mg / kg + ipilimumab 3 mg / kg cohort, and 6 patients in the nivolumab 3 mg / kg + ipilimumab 1 mg / kg cohort continued on post-progression treatment. [Table 5] Data are n (%) unless otherwise stated. All patients were enrolled at least 90 days before database closure.

[0226] At database closure on March 24, 2016, 60 of 98 patients (61%) had died in the nivolumab 3 mg / kg cohort, 36 of 61 patients (59%) in the nivolumab 1 mg / kg plus ipilimumab 3 mg / kg cohort, and 35 of 55 patients (64%) in the nivolumab 3 mg / kg plus ipilimumab 1 mg / kg cohort. Median overall survival was 4.4 months (95% CI 3.0 to 9.3) in the nivolumab 3 mg / kg cohort, 7.7 months (3.6 to 18.0) in the nivolumab 1 mg / kg plus ipilimumab 3 mg / kg cohort, and 6.0 months (3.6 to 11.0) in the nivolumab 3 mg / kg plus ipilimumab 1 mg / kg cohort. One-year overall survival was 33% (95% CI 22–45) in the nivolumab 3 mg / kg cohort, 43% (30–56) in the nivolumab 1 mg / kg plus ipilimumab 3 mg / kg cohort, and 35% (22–48) in the nivolumab 3 mg / g plus ipilimumab 1 mg / kg cohort ( Fig. 4A ).

[0227] Seventy-six (78%) patients in the nivolumab 3 mg / kg cohort, 44 (72%) patients in the nivolumab 1 mg / kg + ipilimumab 3 mg / kg cohort, and 42 (78%) patients in the nivolumab 3 mg / kg + ipilimumab 1 mg / kg cohort had disease progression or died; median progression-free survival was 1.4 months (95% CI 1.4-1.9), 2.6 months (1.4-4.1), and 1.4 months (1.3-2.2), respectively. One-year progression-free survival was 11% (95% CI 5-19) in the nivolumab 3 mg / kg cohort and 19% (9-32) for the nivolumab 1 mg / kg + ipilimumab 3 mg / kg cohort (Figure 4B). The nivolumab 3 mg / kg + ipilimumab 1 mg / kg cohort did not meet the 1-year milestone for progression-free survival at the time of database closure. Two (67%) of three patients in the nivolumab 1 mg / kg + ipilimumab 1 mg / kg cohort had died and one (33%) had a progression event. Nine patients had crossed over from the nivolumab 3 mg / kg cohort to the combination cohort after progression (one to nivolumab 1 mg / kg + ipilimumab 3 mg / kg and eight to nivolumab 3 mg / kg + ipilimumab 1 mg / kg); eight of these patients had further disease progression and one patient in the nivolumab 3 mg / kg + ipilimumab 1 mg / kg cohort withdrew consent and therefore response could not be determined.

[0228] PD-L1 expression was evaluable in 148 (69%) of 216 patient samples, of which 39 (27%) were fresh biopsy samples and 109 (74%) were archived specimens. Twenty-five (17%) had PD-L1 expression ≥1% and 7 (5%) had PD-L1 expression ≥5% (Table 3). In preplanned exploratory analyses of the nivolumab 3 mg / kg, nivolumab 1 mg / kg + ipilimumab 3 mg / kg, and nivolumab 3 mg / kg + ipilimumab 1 mg / kg cohorts, tumor responses occurred in patients independent of PD-L1 expression (Figures 5A–5C, respectively).

[0229] Grade 3 or 4 treatment-related adverse events occurred in 13 of 98 patients (13%) in the nivolumab 3 mg / kg cohort, 18 of 61 patients (30%) in the nivolumab 1 mg / kg + ipilimumab 3 mg / kg cohort, and 10 of 54 patients (19%) in the nivolumab 3 mg / kg + ipilimumab 1 mg / kg cohort (Table 6); no patients in the nivolumab 1 mg / kg + ipilimumab 1 mg / kg cohort had grade 3 or 4 treatment-related adverse events (data not shown). The most commonly reported grade 3 or 4 treatment-related adverse events were lipase elevation (none vs. 5 [8%] vs. none) and diarrhea (none vs. 3 [5%] vs. 1 [2%]). Four (4%) patients in the nivolumab 3 mg / kg cohort, 2 (67%) patients in the nivolumab 1 mg / kg + ipilimumab 1 mg / kg cohort, 18 (30%) patients in the nivolumab 1 mg / kg + ipilimumab 3 mg / kg cohort, and 8 (15%) patients in the nivolumab 3 mg / kg + ipilimumab 1 mg / kg cohort had dose delays due to treatment-related adverse events. Other than malignant neoplasms, the most frequent serious adverse events were dyspnea, experienced by 5 (5%) patients in the nivolumab 3 mg / kg cohort, 2 (3%) patients in the nivolumab 1 mg / kg + ipilimumab 3 mg / kg cohort, and 4 (7%) patients in the nivolumab 3 mg / kg + ipilimumab 1 mg / kg cohort, and diarrhea, experienced by 2 (2%) patients in the nivolumab 3 mg / kg cohort, 4 (7%) patients in the nivolumab 1 mg / kg + ipilimumab 3 mg / kg cohort, and 4 (7%) patients in the nivolumab 3 mg / kg + ipilimumab 1 mg / kg cohort.Seventeen patients discontinued treatment due to treatment-related adverse events: 6 (6%) patients in the nivolumab 3 mg / kg cohort (1 patient each of limbic encephalitis, hyperglycemia, stomatitis, elevated alanine aminotransferase, elevated glutamyltransferase, and interstitial pneumonitis), 7 (11%) patients in the nivolumab 1 mg / kg + ipilimumab 3 mg / kg cohort (1 patient each of colitis, myasthenia gravis, interstitial pneumonitis, cardiomyopathy, and uveitis; 1 patient each of hypothyroidism, hyperglycemia, and elevated alanine aminotransferase; 1 patient each of diarrhea and renal failure), and 4 (7%) patients in the nivolumab 3 mg / kg + ipilimumab 1 mg / kg cohort (1 patient each of colitis, interstitial pneumonitis, and peripheral neuropathy; 1 patient each of dyspnea and interstitial pneumonitis; Table 6). Two patients who received nivolumab 1 mg / kg plus ipilimumab 3 mg / kg died of treatment-related events of myasthenia gravis and worsening renal failure, respectively, and one patient who received nivolumab 3 mg / kg plus ipilimumab 1 mg / kg died of treatment-related interstitial pneumonitis. The following deaths were reported for reasons other than disease progression and study drug toxicity: in the nivolumab 3 mg / kg group, 3 patients (3%) for unknown reasons, 1 patient (1%) for sepsis and multiple organ failure, and 1 patient (1%) for respiratory failure unrelated to study drug; in the nivolumab 1 mg / kg + ipilimumab 3 mg / kg group, 3 patients (5%) for unknown reasons, 1 patient (2%) for subdural hematoma unrelated to study drug, 1 patient (2%) for sedation, 1 patient (2%) for hypovolemic septic shock and septic shock from candidemia, and 1 patient (2%) for abdominal sepsis and secondary intravascular disseminated coagulation; and in the nivolumab 3 mg / kg + ipilimumab 1 mg / kg group, 3 patients (6%) for unknown reasons and 1 patient (2%) for an adverse event unrelated to study drug. [Table 6-1] [Table 6-2] Data are expressed as n (%). The table reports grade 1-2 treatment-related events and all grade 3-4 events in ≥10% of patients in any treatment cohort. Safety analyses included all patients enrolled at least 90 days before database closure; patients with adverse events after transition from nivolumab 3 mg / kg to combination treatment were excluded. Some patients had more than one adverse event. Two patients in the nivolumab 1 mg / kg + ipilimumab 3 mg / kg group died of myasthenia gravis and worsening renal failure, respectively; both events were considered treatment-related. One patient in the nivolumab 3 mg / kg + ipilimumab 1 mg / kg cohort died of interstitial pneumonitis, considered treatment-related.

[0230] Two patients had grade 2 limbic encephalitis: one in the nivolumab 3 mg / kg cohort (reported by the investigator as not treatment-related) and one in the nivolumab 1 mg / kg + ipilimumab 3 mg / kg cohort (reported by the investigator as treatment-related); both events resolved with immunosuppressive treatment. One patient in the nivolumab 3 mg / kg cohort had grade 4 limbic encephalitis (reported by the investigator as treatment-related) that did not resolve with intravenous immunoglobulin and corticosteroid treatment. Treatment-related interstitial pneumonitis occurred in 8 patients, with 6 of the 8 patients resolving with treatment. Outcome was unknown in 1 patient, and 1 patient died.

[0231] One patient who moved from nivolumab 3 mg / kg to nivolumab 1 mg / kg + ipilimumab 3 mg / kg had a treatment-related grade 3 elevation in alanine aminotransferase levels. Five (8%) patients in the nivolumab 1 mg / kg + ipilimumab 3 mg / kg cohort had asymptomatic lipase elevations without clinical signs of grade 3 or 4 pancreatitis (Table 6).

[0232] Objective responses were observed in patients who had received one prior line of therapy and in patients who had received two or more prior lines of therapy (Table 7). Median overall survival and progression-free survival were not significantly different in patients with one versus two or more prior lines of therapy, with the possible exception of the longer progression-free survival of a patient who had received one prior line of therapy who received nivolumab 1 mg / kg + ipilimumab 3 mg / kg (Figures 6A-6D). [Table 7] Data are expressed as n or n (%) unless otherwise indicated. All patients were enrolled at least 90 days prior to database lock.

[0233] In a post-hoc analysis of patients treated with platinum agents as first-line treatment, objective responses were achieved in patients with both platinum-sensitive and platinum-resistant disease (Figures 7A-7C; Table 8). In patients with platinum-sensitive disease, 2 of 55 (4%) in the nivolumab 3 mg / kg cohort and 2 of 25 (8%) in the nivolumab 1 mg / kg + ipilimumab 3 mg / kg cohort received subsequent platinum-based cancer therapy. No patients with platinum-sensitive disease in the nivolumab 3 mg / kg + ipilimumab 1 mg / kg arm received subsequent platinum-based cancer therapy. [Table 8] Data are presented as n (%) unless otherwise stated. All patients were enrolled at least 90 days before database lock. For patients with known response to platinum-based therapy, platinum sensitivity was unknown in 29 patients as follows: nivolumab-3, n=10; nivolumab-1 / ipilimumab-3, n=11; nivolumab-3 / ipilimumab-1, n=8. *Patients who relapsed after ≥90 days of platinum-based chemotherapy. †Patients who did not respond to platinum-based chemotherapy or relapsed after <90 days.

[0234] At database closure on March 30, 2017, blinded central review showed that 11% of patients in the nivolumab 3 mg / kg group and 23% of patients in the nivolumab 1 mg / kg plus ipilimumab 3 mg / kg group had an objective response to treatment. See Table 9. Median time to response was 1.4 months (range, 1.1-4.1 months) in the nivolumab 3 mg / kg group and 2 months (range, 1-4.1 months) in the nivolumab 3 mg / kg plus ipilimumab 1 mg / kg group. Median duration of response was 17.9 months (range, 2.8-34.6) in the nivolumab 3 mg / kg group and 14.2 months (range, 1.5-26.5) in the nivolumab 3 mg / kg plus ipilimumab 1 mg / kg group. Forty-five percent of responders in the nivolumab 3 mg / kg group and 36% of responders in the nivolumab 3 mg / kg + ipilimumab 1 mg / kg group continued to respond after 2 years. [Table 9] a Percentage of responders (nivolumab, n=11; nivolumab + ipilimumab, n=14)

[0235] Tumor PD-L1 expression was evaluated in patients who had an objective response to treatment. See Table 10. Within the non-randomized cohort, PD-L1 expression was not evaluated in 43 patients (27%). Among patients with quantifiable PD-L1 expression (159 patients), 82% had tumors expressing PD-L1 less than 1% and 18% had tumors expressing PD-L1 at least 1% PD-L1. See Figure 9. For patients with tumors expressing PD-L1 at least 1% PD-L1, there was a 9% ORR in the nivolumab 3 mg / kg group and a 10% ORR in the nivolumab 1 mg / kg + ipilimumab 3 mg / kg group. For patients with tumors expressing PD-L1 less than 1%, there was a 14% ORR in the nivolumab 3 mg / kg group and a 32% ORR in the nivolumab 1 mg / kg + ipilimumab 3 mg / kg group. [Table 10]

[0236] Overall survival (OS) was improved with treatment with nivolumab in combination with ipilimumab. See Figure 9. Median OS was 4.1 months (95% CI 3.0-6.8) in the nivolumab 3 mg / kg group and 7.8 months (3.6-14.2) in the nivolumab 3 mg / kg + ipilimumab 1 mg / kg group. One-year OS was 27% in the nivolumab 3 mg / kg group and 40% in the nivolumab 1 mg / kg + ipilimumab 3 mg / kg group. Two-year OS was 14% in the nivolumab 3 mg / kg group and 26% in the nivolumab 1 mg / kg + ipilimumab 3 mg / kg group. Minimum follow-up occurred at 19.6 months (median = 23.3 months) for patients in the nivolumab 3 mg / kg group and 20.2 months (median = 28.6 months) for patients in the nivolumab 3 mg / kg + ipilimumab 1 mg / kg group. Follow-up was calculated as the time from first administration to database closure. In some instances, follow-up was more frequent, e.g., for patients who died before database closure on March 30, 2017.

[0237] Consideration Our findings indicate that nivolumab monotherapy and nivolumab plus ipilimumab provide clinically meaningful activity and a tolerable safety profile in patients with limited-stage or extensive-stage SCLC who have disease progression after at least one prior regimen. The prognosis for patients who have progressed after prior treatment with platinum-based chemotherapy is poor. Patients with advanced SCLC often respond to first-line treatment; however, recurrence is inevitable, and effective options are limited at progression and for patients with platinum-resistant disease. The 2-year survival rate for patients with extensive-stage SCLC was less than 5%.

[0238] Our trial enrolled a heterogeneous patient population with respect to platinum-sensitive or platinum-resistant disease and extent of prior lines of therapy, making comparisons with other second-line trials difficult. Responses and stable disease were seen in all treatment cohorts. Tumor regressions followed both conventional and immune-related patterns of response (prolonged reduction in tumor burden in the presence of new disease). Although the number of patients in the subgroups was small, preliminary analyses showed similar responses between platinum-sensitive and platinum-resistant subgroups and similar activity in patients with one prior regimen versus two or more prior regimens. Responses were durable across treatment arms.

[0239] A phase 2 trial evaluated temozolomide in a similar population of patients whose disease had progressed after one or two prior chemotherapy regimens. Although the proportion of patients who achieved an objective response was comparable to our trial—11 of 48 patients (23%) with platinum-sensitive disease and 2 of 16 patients (13%) with platinum-refractory disease—the median duration of response to temozolomide was lower: 3.5 months (range 1.4–14.7) for all treated patients. Rova-T, a DLL3-targeting antibody-drug conjugate, demonstrated antitumor activity and manageable toxicity in a phase 1 trial of patients with SCLC who had progressed after one or two prior lines of therapy. Objective responses were achieved in 7 of 16 patients (44%) with DLL3 biomarker treatment positivity at the maximum tolerated dose.

[0240] Limitations of our study include that the study cohorts were not randomized and that the study did not allow for formal comparisons between cohorts. Baseline characteristics were generally similar across cohorts, and the combination treatment cohorts demonstrated similar responses, although responses appeared to be deeper with the nivolumab 1 mg / kg + ipilimumab 3 mg / kg regimen, which has also been shown to be effective in previously untreated melanoma.

[0241] The activity of nivolumab as monotherapy or in combination with ipilimumab in platinum-sensitive or line-unrelated patients is a key aspect that distinguishes immune checkpoint inhibitors from topotecan or amrubicin in SCLC. Response to topotecan is driven by chemosensitivity and tumor resistance mutations. In contrast, SCLC2, with its genomically unstable nature, should be sensitive to immune checkpoint blockade by induction or restoration of tumor antigen-driven immune responses. Since lymphocytes are rarely observed in SCLC tumors, one hypothesis is that there is a great need to target the lymphoid compartment with CTLA-4 inhibition in addition to PD-1 inhibition to maximize treatment efficacy.

[0242] There are several studies showing increased activity of PD-1 blockade in patients with PD-L1-expressing NSCLC. However, data including those from this trial suggest that there is a prevalence of PD-L1 expression in SCLC compared with NSCLC. A trial of pembrolizumab, a PD-1 immune checkpoint inhibitor, reported initial and durable responses in 4 of 16 patients (25%) in patients with PD-L1-positive extensive-stage SCLC. In our trial, objective responses were seen in patients regardless of PD-L1 expression, including deep tumor responses in patients with less than 1% PD-L1 tumor expression. Whether PD-L1 expression is predictive of efficacy in SCLC awaits further analysis in larger populations.

[0243] Although more than half of the patients in this trial had received two or more chemotherapy regimens, 1-year overall survival (33% for nivolumab 3 mg / kg and 43% for nivolumab 1 mg / kg + ipilimumab 3 mg / kg) was comparable to or better than that reported in historical trials of second-line topotecan or amrubicin. Consistent with other trials of immune checkpoint inhibitors across multiple solid tumors, and unlike the topotecan trial, findings from our trial showed a flattening of the overall survival curves for the nivolumab 3 mg / kg and nivolumab 1 mg / kg + ipilimumab 3 mg / kg cohorts, suggesting a survival benefit in a subset of patients. However, because this trial was small, it is difficult to determine when this occurs. Consistent with findings from previous randomized trials of immuno-oncology drugs, there appears to be a greater effect of nivolumab or ipilimumab treatment on overall survival than progression-free survival.

[0244] Adverse events were manageable using established safety guidelines. Most toxic effects in the nivolumab 3 mg / kg and nivolumab 3 mg / kg + ipilimumab 1 mg / kg cohorts were mild to moderate, with only 6 (6%) patients in the nivolumab 3 mg / kg group and 4 (7%) patients in the nivolumab 3 mg / kg + ipilimumab 1 mg / kg group discontinuing due to toxicity. Many treatment-related grade 3 or 4 adverse events occurred in the nivolumab 1 mg / kg + ipilimumab 3 mg / kg cohort, with 7 (11%) patients discontinuing due to toxicity. This regimen was used effectively and safely in a phase 3 trial in patients with melanoma, suggesting that this schedule is feasible in patients with SCLC. Fewer treatment-related toxic effects were reported in all cohorts compared with topotecan or amrubicin trials.

[0245] Three patients had limbic encephalitis, and one patient receiving nivolumab 1 mg / kg plus ipilimumab 3 mg / kg died of treatment-related myasthenia gravis. Autoimmune encephalitis and myasthenia gravis, although rare, have been reported with both nivolumab and ipilimumab. The frequency of these events appears to be higher in patients with SCLC compared with other malignancies, likely due to the paraneoplastic neurological syndromes associated with this disease. Treatment-related interstitial pneumonitis was reported in eight patients across all treatment cohorts, leading to death in one patient receiving nivolumab 3 mg / kg plus ipilimumab 1 mg / kg. Disclosure of immune-related adverse events or prior asymptomatic autoimmune disease processes and prompt implementation of safety guidelines for effective management are important.

[0246] Based on these favorable phase 1 / 2 data, phase 3 trials including flat-dose nivolumab (240 mg intravenously every 2 weeks) or two 42-day cycles of nivolumab + ipilimumab (1 mg / kg nivolumab and 3 mg / kg ipilimumab intravenously every 3 weeks followed by nivolumab [240 mg intravenously every 2 weeks]) versus placebo as maintenance treatment (in patients not progressing) after first-line chemotherapy (CheckMate 451, NCT02538666) and nivolumab (240 mg intravenously every 2 weeks) versus single-agent chemotherapy as second-line treatment in SCLC (CheckMate 331, NCT02481830) have been initiated and are currently ongoing.

[0247] Example 2 The Phase 1 / 2 trial detailed in Example 1 is being expanded to include a randomized cohort to further evaluate nivolumab as monotherapy or in combination with ipilimumab in patients with SCLC whose disease has progressed after platinum-based therapy. Here, we report an interim follow-up analysis of the SCLC randomized cohort.

[0248] result Patients with SCLC who had received one or two prior platinum-containing treatment regimens were assigned to one of the following treatment arms in a randomized cohort: nivolumab as monotherapy (3 mg / kg body weight administered intravenously every 2 weeks) or nivolumab + ipilimumab combination treatment (nivolumab 1 mg / kg and ipilimumab 3 mg / kg administered intravenously every 3 weeks for 4 cycles, followed by nivolumab 3 mg / kg administered intravenously every 2 weeks). A total of 242 patients were randomized 3:2 to the nivolumab monotherapy treatment group (n=147) or the nivolumab and ipilimumab combination treatment group (n=95). See Figure 8. The primary endpoint of this trial was the proportion of patients with a confirmed objective response (defined as the number of patients with a best overall response of complete or partial response [by investigator-assessed RECIST, version 1.1 criteria] divided by the number of patients assigned). Objective response rate was the primary endpoint because the goal of this study was to evaluate the antitumor activity of nivolumab monotherapy or in combination with ipilimumab. The median follow-up for the nivolumab 3 mg / kg group was 10.8 months and for the nivolumab 1 mg / kg + ipilimumab 3 mg / kg group was 11.2 months.

[0249] The baseline characteristics of the patients in the randomized cohort are shown in Table 11; all patients in this cohort had been treated with one or two prior platinum-containing regimens. [Table 11]

[0250] Complete responses (CR) were achieved in 2 patients in the randomized cohort (1 patient in the nivolumab 3 mg / kg group and 1 patient in the nivolumab 1 mg / kg + ipilimumab 3 mg / kg group). In the randomized cohort, an objective response rate (ORR) of 12% (95% CI) was achieved in the nivolumab 3 mg / kg group and an ORR of 21% (95% CI) was achieved in the nivolumab 1 mg / kg + ipilimumab 3 mg / kg group in the randomized cohort; whereas, in the non-randomized cohort, an ORR of 11% (95% CI) was achieved in the nivolumab 3 mg / kg group and an ORR of 23% (95% CI) was achieved in the nivolumab 1 mg / kg + ipilimumab 3 mg / kg group. See Figure 10; Table 9. CIs are as follows: nivolumab (randomized): 7, 18; nivolumab + ipilimumab (randomized): 13, 31; nivolumab (non-randomized): 6, 19; nivolumab + ipilimumab (non-randomized): 13, 36.

[0251] The median time to response in the randomized cohort was similar to that in the nonrandomized cohort: 1.5 months in the nivolumab 3 mg / kg group and 1.4 months in the nivolumab 1 mg / kg + ipilimumab 3 mg / kg group.

[0252] In the randomized cohort, a progression-free survival (PFS) rate of 18% (95%CI) was achieved in the nivolumab 3 mg / kg group, and a PFS rate of 30% (95%CI) was achieved in the nivolumab 1 mg / kg + ipilimumab 3 mg / kg group in the randomized cohort; whereas in the non-randomized cohort, a PFS rate of 27% (95%CI) was achieved in the nivolumab 3 mg / kg group, and a PFS rate of 36% (95%CI) was achieved in the nivolumab 1 mg / kg + ipilimumab 3 mg / kg group. See Figure 11.

[0253] In the randomized cohort, overall survival (OS) was 65% (95% CI) in the nivolumab 3 mg / kg group and 64% (95% CI) in the nivolumab 1 mg / kg + ipilimumab 3 mg / kg group; whereas in the non-randomized cohort, OS was 59% (95% CI) in the nivolumab 3 mg / kg group and 72% (95% CI) in the nivolumab 1 mg / kg + ipilimumab 3 mg / kg group. See Figure 12. The minimum follow-up period was 12 weeks.

[0254] The activity and safety of nivolumab monotherapy and nivolumab + ipilimumab combination treatment were also evaluated in pooled cohorts, i.e., the nivolumab 3 mg / kg group from both the randomized and non-randomized cohorts (245 patients combined in the "pooled" nivolumab 3 mg / kg group) and the nivolumab 1 mg / kg + ipilimumab 3 mg / kg group from both the randomized and non-randomized cohorts (156 patients combined in the "pooled" nivolumab 1 mg / kg + ipilimumab 3 mg / kg group).

[0255] The ORR was 11% (95% CI: 8, 6) in the pooled nivolumab 3 mg / kg group and 22% (95% CI: 16, 29) in the pooled nivolumab 1 mg / kg + ipilimumab 3 mg / kg group. See Table 12. [Table 12]

[0256] Treatment-related adverse events (TRAEs) were evaluated in the pooled nivolumab 3 mg / kg group and the pooled nivolumab 1 mg / kg + ipilimumab 3 mg / kg group. TRAEs occurred in 55% of patients in the pooled nivolumab 3 mg / kg group and 73% of patients in the pooled nivolumab 1 mg / kg + ipilimumab 3 mg / kg group, whereas grade 3–4 TRAEs were seen in only 12% of patients in the pooled nivolumab 3 mg / kg group and 37% of patients in the pooled nivolumab 1 mg / kg + ipilimumab 3 mg / kg group. Of these, 78% (31 / 40 in the pooled nivolumab + ipilimumab group) and 45% (5 / 11 in the pooled nivolumab group) resolved. Median time to resolution ranged from 1.8 weeks (gastrointestinal events) to 16.3 weeks (hepatic events) in the pooled nivolumab + ipilimumab groups and from 3.4 weeks (pulmonary events) to not reached (renal and hepatic events) in the pooled nivolumab group. [Table 13]

[0257] There were a total of 5 treatment-related deaths, 4 in the pooled nivolumab plus ipilimumab group due to myasthenia gravis, pneumonitis, seizures / encephalitis, and autoimmune hepatitis (n=1 each) and 1 in the pooled nivolumab group due to pneumonitis. A previously reported death in the nivolumab plus ipilimumab group due to renal failure was subsequently determined to be unrelated to treatment.

[0258] Consideration With a long follow-up of more than 2 years, survival and tumor responses to treatment observed with nivolumab monotherapy or nivolumab and ipilimumab combination therapy remained durable. Efficacy in the randomized cohort was consistent with that in the nonrandomized cohort. Responses to treatment were independent of platinum sensitivity, line of treatment, and / or PD-L1 status.

Claims

[Claim 1] The invention as described in the specification and drawings.

Citation Information

Patent Citations

  • Combination therapy for cancer

    WO2016069727A1